

Set	Items	Description
S1	10515	COACERVATE OR COACERVATION
S2	74108	S1 AND MICROPARTICLE? OR MICROCAPSULE?
S3	5051	S2 AND S1
S4	607	S3 AND BIODEGRADABLE
S5	199	S4 AND ANTIGEN
S6	65	S5 NOT PY>1998
S7	65	RD (unique items)
S8	8644	S7 AND COACERVATE OR COACERVATION
S9	65	S8 AND S7
S10	0	KWIC S9

? d kwic s9

8/8/01

>>>'9' valid only in keyword format
? d kwic

>>>KWIC option is not available in file(s): 399
>>>Item 1 is not within valid item range for file 16
? s9 kwic

S11 0 9 KWIC
? set hi on

Hilight option is not available in file(s) 399
HILIGHT set on as '%'
? t s9/3,ab/1-4

>>>No matching display code(s) found in file(s): 65, 342, 345, 764

9/3,AB/1 (Item 1 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02893542

Utility
METHODS FOR THE DIAGNOSIS OF GLAUCOMA

PATENT NO.: 5,854,415
ISSUED: December 29, 1998 (19981229)
INVENTOR(s): Nguyen, Thai D., Mill Valley, CA (California), US (United States of America)
Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Huang, Weidong, San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-882,238
FILED: June 25, 1997 (19970625)

CROSS REFERENCE TO RELATED APPLICATION

This application is a divisional of U.S. patent application Ser. No. 08-649,432, filed May 17, 1996 U.S. Pat. No. 5,789,169, which is a continuation-in-part of U.S. patent application Ser. No. 08-546,568, filed Oct. 20, 1995, which is a continuation-in-part of U.S. patent application Ser. No. 08-336,235, filed Nov. 3, 1994, which is now U.S. Pat. No. 5,606,043. This application is also a divisional of U.S. patent application

Ser. No. 08-649,432, filed May 17, 1996 U.S. Pat. No. 5,789,169, which is a continuation-in-part of U.S. patent application Ser. No. 08-336,235, filed Nov. 3, 1994, which is now U.S. Pat. No. 5,606,043.

FIELD OF THE INVENTION

The present invention is in the fields of diagnostics, and concerns methods and reagents for diagnosing glaucoma and related disorders. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1532 lines

ABSTRACT

A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

9/3,AB/2 (Item 2 from file: 654)
DIALOG(R) File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02888348

Utility
METHODS FOR THE DIAGNOSIS OF GLAUCOMA

PATENT NO.: 5,849,879
ISSUED: December 15, 1998 (19981215)
INVENTOR(s): Nguyen, Thai D., Mill Valley, CA (California), US (United States of America)
Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Huang, Weidong, Irvine, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-645,900
FILED: May 14, 1996 (19960514)

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Ser. No. 08-546,568, filed Oct. 20, 1995, pending which is a continuation-in-part of U.S. application Ser. No 08-336,235, filed Nov. 3, 1994, now U.S. Pat. No. 5,606,043.

FIELD OF THE INVENTION

The present invention is in the fields of diagnostics, and concerns methods and reagents for diagnosing glaucoma and related disorders. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1514 lines

ABSTRACT

A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

9/3,AB/3 (Item 3 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02860202

Utility
BIOCOMPATIBLE OCULAR IMPLANTS
[Method for treating an eye condition]

PATENT NO.: 5,824,072
ISSUED: October 20, 1998 (19981020)
INVENTOR(s): Wong, Vernon G., Rockville, MD (Maryland), US (United States of America)
ASSIGNEE(s): Oculex Pharmaceuticals, Inc , (A U.S. Company or Corporation), Sunnyvale, CA (California), US (United States of America)
[Assignee Code(s): 41997]
APPL. NO.: 8-698,238
FILED: August 14, 1996 (19960814)

This is a continuation of application Ser. No. 08-437,573 filed May 9, 1995 now abandoned, which is a continuation of application Ser. No. 08-153,184 filed Nov. 15, 1993, now U.S. Pat. No. 5,443,505.

FULL TEXT: 992 lines

ABSTRACT

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

9/3,AB/4 (Item 4 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02842710

Utility
PREPARATION OF IONICALLY CROSS-LINKED POLYPHOSPHAZENE MICROSPHERES BY %COACERVATION%
[Controlling particle size distribution]

PATENT NO.: 5,807,757
ISSUED: September 15, 1998 (19980915)
INVENTOR(s): Andrianov, Alexander K., Belmont, MA (Massachusetts), US (United States of America)
Chen, Jianping, Lexington, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Virus Research Institute, Inc , (A U.S. Company or Corporation), Cambridge, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 38169]
APPL. NO.: 8-675,713
FILED: July 02, 1996 (19960702)

FULL TEXT: 557 lines

ABSTRACT

A method is provided for preparing polyphosphazene microspheres wherein the polyphosphazene microspheres are produced by %coacervation%. A solution containing a polyphosphazene is admixed with a solution containing a salt of a monovalent ion such as a salt of a Group I element (for example, NaCl) to form a dispersion containing polyphosphazene %coacervate% microdroplets. The dispersion then is admixed with a solution containing a salt of a multivalent ion, such as a salt of a Group II element (for example, CaCl sub 2) to form a suspension of polyphosphazene microspheres. The polyphosphazene microspheres then are recovered from the suspension. Such method enables one to obtain high yields of microspheres having a controlled size distribution. Polyphosphazene microspheres containing biological material can be produced by providing a biological material in the polyphosphazene solution that is mixed with the solution containing a salt of a monovalent ion. The biological material may be an %antigen% or other biological material selected from proteins, nucleic acids, polysaccharides and synthetic compounds having biological activity. . .

>No matching display code(s) found in file(s): 65, 342, 345, 764

9/3,AB/5 (Item 5 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02822670

Utility
METHODS FOR THE DIAGNOSIS OF GLAUCOMA
[Using a glucocorticoid induced protein]

PATENT NO.: 5,789,169
ISSUED: August 04, 1998 (19980804)
INVENTOR(s): Nguyen, Thai D., Mill Valley, CA (California), US (United States of America)
Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Huang, Weidong, Irvine, CA (California), US (United States of America)
ASSIGNEE(s): Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-649,432
FILED: May 17, 1996 (19960517)

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Ser. No. 08-546,568, filed Oct. 20, 1995, which is a continuation-in-part of U.S. application Ser. No. 08-336,235, filed Nov. 3, 1994 U.S. Pat. No. 5,606,043. This application is also a continuation-in-part of U.S. application Ser. No. 08-336,235, filed Nov. 3, 1994 U.S. Pat. No. 5,606,043.

FULL TEXT: 1949 lines

ABSTRACT

A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related disease.

9/3,AB/6 (Item 6 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02799052

Utility
BIOCOMPATIBLE OCULAR IMPLANTS
[Method for treating an eye condition]

PATENT NO.: 5,766,242
ISSUED: June 16, 1998 (19980616)
INVENTOR(s): Wong, Vernon G., Rockville, MD (Maryland), US (United States of America)

Kochinke, Frank, San Jose, CA (California), US (United States of America)

ASSIGNEE(s): Oculex Pharmaceuticals, Inc , (A U.S. Company or Corporation), Sunnyvale, CA (California), US (United States of America)

[Assignee Code(s): 41997]

APPL. NO.: 8-615,640

FILED: March 13, 1996 (19960313)

This is a continuation of application Ser. No. 08-431,098 filed 28 Apr., 1995 now abandoned, which is a continuation of 08-153,184 filed 15 Nov., 1993, now U.S. Pat. No. 5,443,505.

FULL TEXT: 950 lines

ABSTRACT

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

9/3,AB/7 (Item 7 from file: 654)

DIALOG(R)File 654:US PAT.FULL.

(c) format only 2001 The Dialog Corp. All rts. reserv.

02710833

Utility

%MICROCAPSULES% OF PREDETERMINED PEPTIDE(S) SPECIFICITY (IES), THEIR PREPARATION AND USES

PATENT NO.: 5,686,113

ISSUED: November 11, 1997 (19971111)

INVENTOR(s): Speaker, Tully J., Philadelphia, PA (Pennsylvania), US (United States of America)

Sultzbaugh, Kenneth J., Philadelphia, PA (Pennsylvania), US (United States of America)

ASSIGNEE(s): Temple University of the Commonwealth System of Higher Education, (A U.S. Company or Corporation), Philadelphia, PA (Pennsylvania), US (United States of America)

[Assignee Code(s): 83508]

APPL. NO.: 8-408,052

FILED: March 21, 1995 (19950321)

FULL TEXT: 1640 lines

ABSTRACT

An aqueous core %microcapsule% has a capsular wall provided with a peptide(s) of pre-determined binding specificity(ies) appended to the surface, the wall being the reaction product of an anionic polymer or salt thereof and a polyamine, salt thereof, mixtures thereof, or mixtures thereof with monoamines. The aqueous core may contain an active ingredient(s), and be targeted for delivery to specific cell tissues. The %microcapsules% are provided as a composition and in a kit with instructions for use in imaging, diagnosis, therapy, vaccination, and other applications.

9/3,AB/8 (Item 8 from file: 654)

DIALOG(R)File 654:US PAT.FULL.

(c) format only 2001 The Dialog Corp. All rts. reserv.

02698233

Utility

METHOD FOR THE TREATMENT OF A TRABECULAR MESHWORK WHOSE CELLS ARE SUBJECT TO INHIBITION OF CELL DIVISION

[Administering to a human an ophthalmologically effective nonsteroidal cyclooxygenase inhibitor and a carrier to increase mitosis; glaucoma; aging; stresses due to environment, oxidation, phagocytosis or glucocorticoids]

PATENT NO.: 5,674,888

ISSUED: October 07, 1997 (19971007)

INVENTOR(s): Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Bloom, Ernest, Alamo, CA (California), US (United States of America)
Fauss, Donald J., San Francisco, CA (California), US (United States of America)

ASSIGNEE(s): University of California, (A U.S. Company or Corporation), Alameda, CA (California), US (United States of America)
[Assignee Code(s): 13234]

APPL. NO.: 8-486,255

FILED: June 07, 1995 (19950607)

The present invention is in the field of therapeutics, and concerns methods and reagents for enhancing the mitotic rate of the cells of a trabecular meshwork whose cells are subject to an inhibition in cell division. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1117 lines

ABSTRACT

The invention concerns the recognition that certain non-steroidal anti-inflammatory agents can overcome or ameliorate limitations on trabecular meshwork cell division produced by environmental stresses (e.g., oxidative or phagocytic injury, or glucocorticoid exposure), and thus can be used to prevent or treat loss of trabecular cells found in certain forms of glaucoma and in normal aging. The use of such non-steroidal anti-inflammatory agents can ameliorate the severity, or prevent glaucoma.

9/3,AB/9 (Item 9 from file: 654)

DIALOG(R)File 654:US PAT.FULL.

(c) format only 2001 The Dialog Corp. All rts. reserv.

02663061

Utility

METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ADJUVANTS

[Polylactide or polylactide-glycolide copolymer]

PATENT NO.: 5,643,605

ISSUED: July 01, 1997 (19970701)

INVENTOR(s): Cleland, Jeffrey L., San Carlos, CA (California), US (United States of America)
Lim, Amy, San Bruno, CA (California), US (United States of America)
Powell, Michael Frank, San Francisco, CA (California), US (United States of America)

ASSIGNEE(s): Genentech, Inc, (A U.S. Company or Corporation), South San Francisco, CA (California), US (United States of America)
[Assignee Code(s): 7579]

APPL. NO.: 8-460,363

FILED: June 02, 1995 (19950602)

This application is a continuation of application Ser. No. 08-143,332,

filed Oct. 25, 1993 now abandoned.

FULL TEXT: 1731 lines

ABSTRACT

Methods and compositions are provided for the encapsulation of adjuvants in PLGA microspheres for use as vaccines. Mixtures of microspheres are provided which release adjuvant at desired intervals to provide boosts with adjuvant.

9/3,AB/10 (Item 10 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02623272

Utility

METHODS FOR THE DIAGNOSIS OF GLAUCOMA

[Specific nucleic acid encoded human trabecular meshwork induced glucocorticoid response protein]

PATENT NO.: 5,606,043

ISSUED: February 25, 1997 (19970225)

INVENTOR(s): Nguyen, Thai D., Mill Valley, CA (California), US (United States of America)
Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Huang, Weidong, San Francisco, CA (California), US (United States of America)

ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)

[Assignee Code(s): 13234]

APPL. NO.: 8-336,235

FILED: November 03, 1994 (19941103)

FIELD OF THE INVENTION

The present invention is in the fields of diagnostics, and concerns methods and reagents for diagnosing glaucoma and related disorders. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1303 lines

ABSTRACT

A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

>>No matching display code(s) found in file(s): 65, 342, 345, 764

9/3,AB/11 (Item 11 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02616460

Utility

METHODS FOR THE CYTO-PROTECTION OF THE TRABECULAR MESHWORK

[Administering a non-steroidal antiinflammatory agent preventing cell lose in eye disorders]

PATENT NO.: 5,599,535
ISSUED: February 04, 1997 (19970204)
INVENTOR(s): Polansky, Jon R., Mill Valley, CA (California), US (United States of America)
Bloom, Ernest, Alamo, CA (California), US (United States of America)
Fauss, Donald J., San Francisco, CA (California), US (United States of America)
ASSIGNEE(s): Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-479,185
FILED: June 07, 1995 (19950607)

FIELD OF THE INVENTION

The present invention is in the field of therapeutics, and concerns methods and reagents for protecting the cells of the trabecular meshwork from agents or processes that would otherwise result in trabecular cell loss. This invention was supported with Government funds (NIH EY02477 and NIH EY 08905-02). The Government has certain rights in this invention.

FULL TEXT: 1164 lines

ABSTRACT

The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury to the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells. Such treatment can ameliorate the severity, or prevent, glaucoma.

9/3,AB/12 (Item 12 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02581900

Utility

SYNTHETIC GANGLIOSIDE DERIVATIVES

[Immunosuppressant]

PATENT NO.: 5,567,684
ISSUED: October 22, 1996 (19961022)
INVENTOR(s): Ladisch, Stephan, Chevy Chase, MD (Maryland), US (United

States of America)
Hasegawa, Akira, Gifu, JP (Japan)
ASSIGNEE(s): The Regents of The University of California, (A U.S. Company
or Corporation), Oakland, CA (California), US (United States
of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-305,832
FILED: September 14, 1994 (19940914)

FULL TEXT: 980 lines

ABSTRACT

Synthetic compounds which are useful for suppressing an immune response are disclosed. The synthetic compounds have the formula [See structure in original document] wherein A is a carbohydrate moiety which corresponds to the carbohydrate moiety of a naturally occurring ganglioside, n is 5 to 20 and m is to 20. Also presented are methods for suppressing an immune response in an animal and compositions of matter employing the compounds as shown above.

9/3,AB/13 (Item 13 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02545335

Utility

METHOD OF PRODUCING SUSTAINED-RELEASE PREPARATION

[Allowing water soluble polypeptide to diffuse into matrix of lactic acid-glycolic acid copolymer]

PATENT NO.: 5,534,269
ISSUED: July 09, 1996 (19960709)
INVENTOR(s): Igari, Yasutaka, Kobe, JP (Japan)
Yamamoto, Kazumichi, Nara, JP (Japan)
Okamoto, Kayoko, Osaka, JP (Japan)
Yamagata, Yutaka, Kobe, JP (Japan)
ASSIGNEE(s): Takeda Chemical Industries, Ltd, (A Non-U.S. Company or
Corporation), Osaka, JP (Japan)
[Assignee Code(s): 82624]
APPL. NO.: 8-270,838
FILED: July 05, 1994 (19940705)
PRIORITY: 5-165793, JP (Japan), July 5, 1993 (19930705)
6-081765, JP (Japan), April 20, 1994 (19940420)

FULL TEXT: 1345 lines

ABSTRACT

A method of producing a sustained-release preparation which includes permitting a water-soluble polypeptide to permeate into a %biodegradable% matrix in the aqueous solution. The production method of the present invention makes possible the permeation of a water-soluble polypeptide into a %biodegradable% matrix without bringing the water-soluble polypeptide into contact with an organic solvent. Hence the water-soluble polypeptide is prepared without affecting the water-soluble polypeptide bioactivity and is thus effective for use as a pharmaceutical.

9/3,AB/14 (Item 14 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02453521

Utility

METHODS AND COMPOSITIONS FOR THE ORAL DELIVERY OF THERAPEUTIC AGENTS

[Polyacrylic acid, crosslinked alginate]

PATENT NO.: 5,451,411
ISSUED: September 19, 1995 (19950919)
INVENTOR(s): Gombotz, Wayne R., Kirkland, WA (Washington), US (United States of America)
Mumper, Russell J., Greenville, NC (North Carolina), US (United States of America)
Hoffman, Allan S., Seattle, WA (Washington), US (United States of America)
Bouchard, Lisa S., Renton, WA (Washington), US (United States of America)
ASSIGNEE(s): Bristol Myers Squibb Company, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
University of Washington, (A U.S. Company or Corporation), Seattle, WA (Washington), US (United States of America)
[Assignee Code(s): 2937; 22921]
APPL. NO.: 8-138,367
FILED: October 15, 1993 (19931015)

FULL TEXT: 1037 lines

ABSTRACT

Alginate beads are employed as a site specific oral delivery system for cationic therapeutic agents, such as TGF- beta sub 1, designed to target the agents to the luminal side of the small intestine. Improved delivery of bioactive material is obtained by: 1) incorporating selected polyanions in the alginate beads to shield the cationic therapeutic agent from interaction with alginate and/or 2) acid treating alginate beads containing the therapeutic agents to reduce the molecular weight of alginate and its interaction with the agents. Enhanced bioactivity of therapeutic agents released from the alginate is attributed to the ability of polyacrylic acid to shield the agents from interaction with lower molecular fragments of acid treated alginate.

9/3,AB/15 (Item 15 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02444728

Utility
BIOCOMPATIBLE OCULAR IMPLANTS

PATENT NO.: 5,443,505
ISSUED: August 22, 1995 (19950822)
INVENTOR(s): Wong, Vernon G., Rockville, MD (Maryland), US (United States of America)
Kochinke, Frank, San Jose, CA (California), US (United States of America)
ASSIGNEE(s): Oculex Pharmaceuticals, Inc, (A U.S. Company or Corporation), Palo Alto, CA (California), US (United States of America)
[Assignee Code(s): 41997]
APPL. NO.: 8-153,184
FILED: November 15, 1993 (19931115)

FULL TEXT: 983 lines

ABSTRACT

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant

levels outside the site of administration.

9/3,AB/16 (Item 16 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02380671

Utility

CAPSULE WHICH COMPRISES A COMPONENT SUBJECT TO DEGRADATION AND A COMPOSITE POLYMER

[Enzyme-containing detergents; hydrophobic polymer core, hydrophilic water soluble polymer attached to the hydrophobic core]

PATENT NO.: 5,385,959
ISSUED: January 31, 1995 (19950131)
INVENTOR(s): Tsaur, Liang S., Norwood, NJ (New Jersey), US (United States of America)
Aronson, Michael P., West Nyack, NY (New York), US (United States of America)
ASSIGNEE(s): Lever Brothers Company, Division of Conopco, Inc, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 23809]
APPL. NO.: 8-36,766
FILED: March 25, 1993 (19930325)

This application is a continuation-in-part of 07-875,914 filed Apr. 29, 1992, now abandoned.

FULL TEXT: 1656 lines

ABSTRACT

The present invention relates to a capsule for use in heavy duty liquid compositions which capsule comprises:

- (1) a component subject to degradative attack; and
- (2) a composite polymer which in turn comprises a hydrophilic portion and hydrophobic polymer core particle.

9/3,AB/17 (Item 17 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02359434

Utility

GANGLIOSIDES WITH IMMUNOSUPPRESSIVE CERAMIDE MOIETIES

[Autoimmune diseases]

PATENT NO.: 5,366,963
ISSUED: November 22, 1994 (19941122)
INVENTOR(s): Ladisch, Stephan, Chevy Chase, MD (Maryland), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-21,734
FILED: February 23, 1993 (19930223)

This is a continuation of copending application(s) Ser. No. 07-738,591 filed on Jul. 31, 1991, now abandoned.

FULL TEXT: 844 lines

ABSTRACT

A method for suppressing immune responses in animals by administering a mixture of gangliosides to the animal where the gangliosides have heterogeneous ceramide structures containing fatty acid portions with carbon chain lengths of 21-30 or less than 18 carbon atoms. Ganglioside mixtures which are homogeneous with respect to the fatty acid portion are also effective immunosuppressive agents when the carbon chain length of the fatty acid portion is less than 18. Compositions containing the above specified ganglioside mixtures are also disclosed.

9/3,AB/18 (Item 18 from file: 654)
DIALOG(R) File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02264657

Utility

PROTEASE CONTAINING HEAVY DUTY LIQUID DETERGENT COMPOSITIONS COMPRISING CAPSULES COMPRISING NON-PROTEOLYTIC ENZYME AND COMPOSITE POLYMER [Anionic, nonionic, cationic, ampholytic, or zwitterion surfactant, proteolytic enzyme, and a composite polymer comprising hydrophobic core particles and hydrophilic water soluble polymer attached to the core]

PATENT NO.: 5,281,357
ISSUED: January 25, 1994 (19940125)
INVENTOR(s): Morgan, Leslie J., Jersey City, NJ (New Jersey), US (United States of America)
Aronson, Michael P., West Nyack, NY (New York), US (United States of America)
Tsaur, Liang S., Norwood, NJ (New Jersey), US (United States of America)
Hessel, John F., Metuchen, NJ (New Jersey), US (United States of America)
McCown, Jack T., Cresskill, NJ (New Jersey), US (United States of America)
ASSIGNEE(s): Lever Brothers Company, Division of Conopco, Inc , (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 23809]
APPL. NO.: 8-37,068
FILED: March 25, 1993 (19930325)

FULL TEXT: 1652 lines

ABSTRACT

The present invention relates to a protease containing heavy duty liquid composition comprising
(a) a capsule which comprises a non-proteolytic enzyme; and
(b) a composite polymer which in turn comprises a hydrophilic portion and hydrophobic polymer core particles.

9/3,AB/19 (Item 19 from file: 654)
DIALOG(R) File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02264656

Utility

HEAVY DUTY LIQUID DETERGENT COMPOSITIONS CONTAINING NON-PROTEOLYTIC ENZYMES

COMPRISING CAPSULES COMPRISING PROTEOLYTIC ENZYME AND COMPOSITE POLYMER
[Cores and capsules]

PATENT NO.: 5,281,356
ISSUED: January 25, 1994 (19940125)
INVENTOR(s): Tsaur, Liang S., Norwood, NJ (New Jersey), US (United States of America)
Aronson, Michael P., West Nyack, NY (New York), US (United States of America)
Morgan, Leslie J., Jersey City, NJ (New Jersey), US (United States of America)
Hessel, John F., Metuchen, NJ (New Jersey), US (United States of America)
McCown, Jack T., Cresskill, NJ (New Jersey), US (United States of America)
Gormley, John L., Midland Park, NJ (New Jersey), US (United States of America)
ASSIGNEE(s): Lever Brothers Company, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 49528]
APPL. NO.: 8-37,053
FILED: March 25, 1993 (19930325)
DISCLAIMER: January 01, 2011 (20110101)

FULL TEXT: 1705 lines

ABSTRACT

The present invention relates to heavy duty liquid compositions containing non-proteolytic enzyme or enzymes and comprising (a) a capsule which comprises a proteolytic enzyme and (b) a composite polymer which in turn comprises a hydrophilic portion and hydrophobic polymer core particles.

9/3,AB/20 (Item 20 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02264655

Utility

HEAVY DUTY LIQUID DETERGENT COMPOSITIONS CONTAINING A CAPSULE WHICH COMPRISES A COMPONENT SUBJECT TO DEGRADATION AND A COMPOSITE POLYMER [Anionic, nonionic, cationic, ampholytic, or zwitterion surfactant capsules comprising enzymes and a composite polymer comprising hydrophobic core particles and hydrophilic water soluble polymer attached to the core]

PATENT NO.: 5,281,355
ISSUED: January 25, 1994 (19940125)
INVENTOR(s): Tsaur, Liang S., Norwood, NJ (New Jersey), US (United States of America)
Aronson, Michael P., West Nyack, NY (New York), US (United States of America)
Morgan, Leslie J., Jersey City, NJ (New Jersey), US (United States of America)
Hessel, John F., Metuchen, NJ (New Jersey), US (United States of America)
McCown, Jack T., Cresskill, NJ (New Jersey), US (United States of America)
ASSIGNEE(s): Lever Brothers Company, Division of Conopco, Inc , (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 23809]
EXTRA INFO: Assignment transaction [Reassigned], recorded March 21, 1994 (19940321)
APPL. NO.: 8-36,775

FILED:

March 25, 1993 (19930325)

RELATED APPLICATIONS

The present application is a continuation-in-part of U.S. Ser. No. 07-875,872 filed Apr. 29, 1992, now abandoned.

FULL TEXT: 1716 lines

ABSTRACT

The present invention relates to a heavy duty liquid compositions comprising (a) a capsule comprising a component subject to degradative attach; and (b) a composite polymer which in turn comprises a hydrophilic portion and hydrophobic polymer core particles.

? t s9/3,ab/21-40

>>>No matching display code(s) found in file(s): 65, 342, 345, 764

9/3,AB/21 (Item 21 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02132433

Utility

%BIODEGRADABLE% OCULAR IMPLANTS
[Sustained release drug delivery]

PATENT NO.: 5,164,188
ISSUED: November 17, 1992 (19921117)
INVENTOR(s): Wong, Vernon G., Rockville, MD (Maryland), US (United States of America)
ASSIGNEE(s): Visionex, Inc , (A U.S. Company or Corporation), Sunnyvale, CA (California), US (United States of America)
[Assignee Code(s): 21211]
EXTRA INFO: Assignment transaction [Reassigned], recorded January 30, 1995 (19950130)
APPL. NO.: 7-440,344
FILED: November 22, 1989 (19891122)

FULL TEXT: 525 lines

ABSTRACT

Encapsulated agents are employed for introduction into the suprachoroid of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

9/3,AB/22 (Item 22 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

01911731

Utility

CONTROLLED RELEASE OF MACROMOLECULAR POLYPEPTIDES
[MICRO-SUSPENSION OF WATER SOLUBLE COMPONENTS IN POLYLACTIDE MATRIC]

PATENT NO.: 4,962,091
ISSUED: October 09, 1990 (19901009)
INVENTOR(s): Eppstein, Deborah A., Palo Alto, CA (California), US (United States of America)
Schryver, Brian B., Redwood City, CA (California), US (United States of America)
ASSIGNEE(s): Syntex (U S A) Inc , (A U.S. Company or Corporation), Palo Alto, CA (California), US (United States of America)
[Assignee Code(s): 82370]
APPL. NO.: 6-866,625
FILED: May 23, 1986 (19860523)

FULL TEXT: 1109 lines

ABSTRACT

An active agent delivery system for the controlled administration of macromolecular polypeptides which comprises a micro-suspension of water-soluble components in a polylactide matrix.

9/3,AB/23 (Item 23 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

01865521

Utility

MAMMAL IMMUNIZATION

[INOCULATING WITH MICROENCAPSULATED %ANTIGEN%]

PATENT NO.: 4,919,929
ISSUED: April 24, 1990 (19900424)
INVENTOR(s): Beck, Lee R., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): Stolle Research & Development Corporation, (A U.S. Company or Corporation), Birmingham, AL (Alabama), US (United States of America)
[Assignee Code(s): 6083]
EXTRA INFO: Assignment transaction [Reassigned], recorded September 21, 1998 (19980921)
APPL. NO.: 6-910,297
FILED: September 17, 1986 (19860917)

This application is a continuation of application Ser. No. 576,001, filed Feb. 1, 1984, now abandoned.

FULL TEXT: 919 lines

ABSTRACT

Mammals are brought to a specific state of immunization by administering an amount of an antigenic substance sufficient to elicit an immunization response to said mammal, said antigenic substance being incorporated within a shaped structure of a biocompatible matrix material.

9/3,AB/24 (Item 1 from file: 653)
DIALOG(R)File 653:US Patents Fulltext
(c) format only 2001 The Dialog Corp. All rts. reserv.

01690222

Utility

ACTIVE/PASSIVE IMMUNIZATION OF THE INTERNAL FEMALE REPRODUCTIVE ORGANS

[Duplicating menstrual cycle of host while administering antibody or %antigen% by depositing estrogen, progestin, antibody or %antigen% containing %microparticles% in vagina]

PATENT NO.: 4,756,907
ISSUED: July 12, 1988 (19880712)
INVENTOR(s): Beck, Lee R., Birmingham, AL (Alabama), US (United States of America)
Flowers, Jr. Charles F., Birmingham, AL (Alabama), US (United States of America)
Cowsar, Donald R., Birmingham, AL (Alabama), US (United States of America)
Tanquary, Albert C., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): Stolle Research & Development Corp , (A U.S. Company or Corporation), Lebanon, OH (Ohio), US (United States of America)
[Assignee Code(s): 6083]

EXTRA INFO: Assignment transaction [Reassigned], recorded May 6,
1996 (19960506)
Assignment transaction [Reassigned], recorded January 9,
1997 (19970109)
Expired, effective July 12, 2000 (20000712), recorded in O.G.
of September 12, 2000 (20000912)
APPL. NO.: 6-822,236
FILED: January 24, 1986 (19860124)

This is a continuation of application Ser. No. 217,746, filed Dec. 18, 1980, now U.S. Pat. No. 4,585,651 which is a continuation of application Ser. No. 952,109 now abandoned, filed Oct. 17, 1978.

FULL TEXT: 1196 lines

ABSTRACT

Antibody or %antigen% containing %microparticles% for the active or passive immunization of the internal female reproductive organs, comprising: %microparticles% of an %antigen% or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said %microparticles% capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

9/3,AB/25 (Item 2 from file: 653)
DIALOG(R)File 653:US Patents Fulltext
(c) format only 2001 The Dialog Corp. All rts. reserv.

01664056

Utility

ACTIVE/PASSIVE IMMUNIZATION OF THE INTERNAL FEMALE REPRODUCTIVE ORGANS
[ANTIGENS, ANTIBODIES, IMMUNIZATION]

PATENT NO.: 4,732,763
ISSUED: March 22, 1988 (19880322)
INVENTOR(s): Beck, Lee R., Birmingham, AL (Alabama), US (United States of America)
Flowers, Charles F., Birmingham, AL (Alabama), US (United States of America)
Cowsar, Donald R., Birmingham, AL (Alabama), US (United States of America)
Tanquary, Albert C., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): Stolle Research and Development Corporation, (A U.S. Company or Corporation), Cincinnati, OH (Ohio), US (United States of America)
[Assignee Code(s): 6083]
EXTRA INFO: Assignment transaction [Reassigned], recorded May 6, 1996 (19960506)
Assignment transaction [Reassigned], recorded January 9, 1997 (19970109)
Expired, effective March 22, 2000 (20000322), recorded in O.G. of May 30, 2000 (20000530)
APPL. NO.: 6-655,989
FILED: September 28, 1984 (19840928)

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 121,480, filed Feb. 14, 1980 which in turn is a continuation-in-part of application Ser. No. 952,109, filed Oct. 17, 1978, now both abandoned.

FULL TEXT:

1200 lines

ABSTRACT

Antibody or %antigen% containing %microparticles% for the active or passive immunization of the internal female reproductive organs, comprising: %microparticles% of an %antigen% or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said %microparticles% capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

9/3,AB/26 (Item 3 from file: 653)
DIALOG(R)File 653:US Patents Fulltext
(c) format only 2001 The Dialog Corp. All rts. reserv.

01504608

Utility

ACTIVE/PASSIVE IMMUNIZATION OF THE INTERNAL FEMALE REPRODUCTIVE ORGANS
[ANTIFERTILITY VACCINE]

PATENT NO.: 4,585,651
ISSUED: April 29, 1986 (19860429)
INVENTOR(s): Beck, Lee R., Birmingham, AL (Alabama), US (United States of America)
Flowers, Jr. Charles F., Birmingham, AL (Alabama), US (United States of America)
Cowsar, Donald R., Birmingham, AL (Alabama), US (United States of America)
Tanquary, Albert C., Birmingham, AL (Alabama), US (United States of America)
ASSIGNEE(s): Stolle Research & Development Corporation, (A U.S. Company or Corporation), Lebanon, OH (Ohio), US (United States of America)
[Assignee Code(s): 6083]
EXTRA INFO: Assignment transaction [Reassigned], recorded May 6, 1996 (19960506)
Assignment transaction [Reassigned], recorded January 9, 1997 (19970109)
Expired, effective April 29, 1998 (19980429), recorded in O.G. of July 7, 1998 (19980707)
APPL. NO.: 6-217,746
FILED: December 18, 1980 (19801218)

This is a continuation of application Ser. No. 952,109, filed Oct. 17, 1978, now abandoned.

FULL TEXT: 964 lines

ABSTRACT

Antibody or %antigen% containing %microparticles% for the active or passive immunization of the internal female reproductive organs, comprising: %microparticles% of an %antigen% or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said %microparticles% capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

9/3,AB/27 (Item 4 from file: 653)
DIALOG(R)File 653:US Patents Fulltext
(c) format only 2001 The Dialog Corp. All rts. reserv.

Utility

%BIODEGRADABLE%, IMPLANTABLE DRUG DELIVERY DEPOTS, AND METHOD FOR PREPARING AND USING THE SAME

[MATRICES OF A POLYLACTAM COPOLYMER OF GLUTAMIC ACID AND MONOETHYL GLUTAMATE; CONTROLLED AND SUSTAINED RELEASE]

PATENT NO.: 4,450,150
 ISSUED: May 22, 1984 (19840522)
 INVENTOR(s): Sidman, Kenneth R., Wayland, MA (Massachusetts), US (United States of America)
 ASSIGNEE(s): Arthur D Little, Inc , (A U.S. Company or Corporation), Cambridge, MA (Massachusetts), US (United States of America)
 [Assignee Code(s): 50200]
 EXTRA INFO: Expired, effective May 22, 1996 (19960522), recorded in O.G. of July 30, 1996 (19960730)
 APPL. NO.: 6-262,149
 FILED: May 11, 1981 (19810511)
 PRIORITY: 199552, CA (Canada), May 10, 1974 (19740510)
 6744-74, CH (Switzerland), May 16, 1974 (19740516)
 2424169, DE (Germany), May 17, 1974 (19740517)
 74-34307, FR (France), November 10, 1974 (19741110)
 21361-74, GB (United Kingdom), May 14, 1974 (19740514)
 48-54595, JP (Japan), May 17, 1974 (19740517)

This application is a continuation-in-part of my application Ser. No. 896,552 filed Apr. 14, 1978 now abandoned, which was filed as a continuation-in-part of my application Ser. No. 596,444 filed July 16, 1975, which in turn is a continuation-in-part of my application Ser. No. 361,182 filed May 17, 1973, and now abandoned.

FULL TEXT: 1081 lines

ABSTRACT

An implantable drug deliver depot comprising a hydrophilic poly(glutamic acid-co-ethyl glutamate) structure having one or more substances, e.g., drugs and/or diagnostic agents physically contained therein. The drug or diagnostic agent is released by its permeation of and diffusion through the copolymer structure. The depot may be designed to release the substance or substances at predetermined rates and in predetermined sequence. The copolymer structure ultimately biodegrades to glutamic acid. Among the preferred configurations for the depots are rods and closed-end capsules.

9/3,AB/28 (Item 1 from file: 349)
 DIALOG(R)File 349:PCT Fulltext
 (c) 2001 WIPO/MicroPat. All rts. reserv.

00606160

< i> ENTEROCOCCUS FAECALIS < /i> POLYNUCLEOTIDES AND POLYPEPTIDES
 POLYNUCLEOTIDES ET POLYPEPTIDES D'< i> ENTEROCOCCUS FAECALIS < /i>

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, HUMAN GENOME SCIENCES, INC. , 9410 Key West Avenue, Rockville, MD 20850 , US

Inventor(s):

KUNSCH Charles A, KUNSCH, Charles, A. , 4083 Spalding Hollow, Norcross, GA 30092 , US

DILLON Patrick J, DILLON, Patrick, J. , 1055 Snipe Court, Carlsbad, CA 92009 , US

BARASH Steven C, BARASH, Steven, C. , 582 College Parkway &303, Rockville, MD 20850 , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9850555 A2 19981112

Application: WO 98US8985 19980504 (PCT/WO US9808985)
Priority Application: US 9744031 19970506; US 9746655 19970516; US
9766009 19971114

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD
MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US
UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN
ML MR NE SN TD TG

Publication Language: English
Filing Language: English
Fulltext Word Count: 491623

English Abstract

The present invention provides polynucleotide sequences of the genome of
< i> Enterococcus faecalis < /i> , polypeptide sequences encoded by the
polynucleotide sequences, corresponding polynucleotides and polypeptides,
vectors and hosts comprising the polynucleotides, and assays and other
uses thereof. The present invention further provides polynucleotide and
polypeptide sequence information stored on computer readable media, and
computer-based systems and methods which facilitate its use.

French Abstract

Cette invention, qui a trait a des sequences polynucleotidiques du genome
d'< i> Enterococcus faecalis < /i> , a des sequences polypeptidiques
codees par les sequences polynucleotidiques, aux polynucleotides et
polypeptides correspondants, ainsi qu'a des vecteurs et a des hotes
comportant les polynucleotides, porte egalement sur des epreuves les
concernant et d'autres utilisations qui en sont faites. Elle concerne, de
surcroit, une information relative aux sequences polynucleotidiques et
polypeptidiques stockees sur des supports informatiques ainsi que des
systemes et des methodes informatiques facilitant leur utilisation.

9/3,AB/29 (Item 2 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00605754

NOVEL PRODRUGS COMPRISING FLUORINATED AMPHIPHILES
NOUVEAUX PROMEDICAMENTS RENFERMANT DES AMPHIPHILES FLUORES

Patent Applicant/Assignee:

IMARX PHARMACEUTICAL CORP, IMARX PHARMACEUTICAL CORP. , 1635 East 18th
Street, Tucson, AZ 85749 , US

Inventor(s):

UNGER Evan C, UNGER, Evan, C. , 13365 East Camino La Cebadilla, Tucson,
AZ 85749 , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9850041 A1 19981112

Application: WO 98US7712 19980415 (PCT/WO US9807712)

Priority Application: US 97851780 19970506; US 97887215 19970702

Designated States: AU BR CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE

Publication Language: English
Filing Language: English
Fulltext Word Count: 56382

English Abstract

The present invention describes, < i> inter alia < /i> , novel prodrugs
comprising fluorinated amphiphiles, compositions comprising the novel
prodrugs, and methods of use of the prodrugs and compositions.

French Abstract

La presente invention concerne, entre autres, de nouveaux promedicaments
renfermant des amphiphiles, des compositions contenant ces nouveaux
promedicaments, ainsi que des procedes d'utilisation de ces

promedicaments et de ces compositions.

9/3,AB/30 (Item 3 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00605753

NOVEL LIPID SOLUBLE STEROID PRODRUGS
NOUVEAUX PROMEDICAMENTS STEROIDES LIPOSOLUBLES

Patent Applicant/Assignee:

IMARX PHARMACEUTICAL CORP, IMARX PHARMACEUTICAL CORP. , 1635 East 18th
Street, Tucson, AZ 85749 , US

Inventor(s):

UNGER Evan C, UNGER, Evan, C. , 13365 East Camino La Cebadilla, Tucson,
AZ 85749 , US

SHEN DeKang, SHEN, DeKang , 2602 W. Aiden Street, Tucson, AZ 85745 , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9850040 A1 19981112

Application: WO 98US7492 19980415 (PCT/WO US9807492)

Priority Application: US 97851780 19970506

Designated States: AU BR CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE

Publication Language: English

Filing Language: English

Fulltext Word Count: 55680

English Abstract

The present invention is directed to novel lipid soluble steroid
prodrugs, compositions comprising steroid prodrugs, and uses of the same.

French Abstract

La presente invention concerne de nouveaux promedicaments steroïdes
liposolubles, des compositions renfermant des promedicaments steroïdes,
ainsi que leur utilisation.

9/3,AB/31 (Item 4 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00604065

PEPTIDES WHICH ENHANCE TRANSPORT OF AN ACTIVE AGENT ACROSS TISSUES AND
COMPOSITIONS AND METHODS OF USING THE SAME

PEPTIDES FAVORISANT LE TRANSPORT D'UN AGENT ACTIF DANS LES TISSUS,
COMPOSITIONS LES RENFERMANT ET LEURS PROCEDES D'UTILISATION

Patent Applicant/Assignee:

ELAN CORPORATION PLC, ELAN CORPORATION, PLC , Lincoln House, Lincoln
Place, Dublin 2 , IE

CYTOGEN CORPORATION, CYTOGEN CORPORATION , 600 College Road East CN-5308,
Princeton, NJ 08540-5308 , US

Inventor(s):

O'MAHONY Daniel Joseph, O'MAHONY, Daniel, Joseph , 75 Avoca Park, Avoca
Avenue, Blackrock, County Dublin , IE

ALVAREZ Vernon Leon, ALVAREZ, Vernon, Leon , 187 Rice Drive, Morrisville,
PA 19067 , US

SEVESO Michela, SEVESO, Michela , Apartment 89, Marlborough Court,
Marlborough Street, Dublin 1 , IE

Patent and Priority Information (Country, Number, Date):

Patent: WO 9851825 A1 19981119

Application: WO 98US10079 19980515 (PCT/WO US9810079)

Priority Application: US 97857046 19970515

Designated States: AL AU BB BG BR CA CN CU EE GE HU IL IS JP KP KR LK LT LV
MK MX NO NZ PL RO RU SG SI SK TR TT UA US VN GH GM KE LS MW SD SZ UG ZW
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

English Abstract

Targeting agents that are capable of permitting or facilitating transport of an active agent through a human or animal gastro-intestinal tissue. These targeting agents are peptides or their derivatives (e.g., fragments) and peptidomimetics thereof, and the nucleotide sequences coding for the peptides and derivatives. The targeting agents have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Therapeutic methods of administration, pharmaceutical compositions and formulations based on the targeting agent peptides are also provided. Preferably, the active agent is a drug or drug-containing nano- or microparticle%.

French Abstract

L'invention concerne des agents de ciblage permettant ou facilitant le transport d'un agent actif dans des tissus gastro- intestinaux humains ou animaux. Ces agents de ciblage sont des peptides, ou leurs derives (par exemple des fragments) et leur peptidomimetique, ainsi que les sequences codant ces peptides et leurs derives. L'utilisation de ces agents de ciblage facilite le transport d'agents actifs de la lumiere du tractus gastro-intestinal a l'ensemble du systeme cardio-vasculaire, et/ou cible lesdits agents actifs vers ledit tractus gastro-intestinal. L'invention concerne egalement des procedes d'administration therapeutiques ainsi que des compositions et des formulations pharmaceutiques a base des peptides agents de ciblage. L'agent actif est de preference un medicament, ou une microparticule ou une nanoparticule renfermant un medicament.

9/3,AB/32 (Item 5 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00603717

RANDOM PEPTIDES THAT BIND TO GASTRO-INTESTINAL TRACT (GIT) TRANSPORT RECEPTORS AND RELATED METHODS
PEPTIDES ALEATOIRES SE LIANT AU RECEPTEURS DE TRANSPORT DU TRACTUS GASTROINTESTINAL (GIT) ET PROCEDES Y RELATIFS

Patent Applicant/Assignee:

CYTOGEN CORPORATION, CYTOGEN CORPORATION , 600 College Road East,
Princeton, NJ 08540 , US

ELAN CORPORATION PLC, ELAN CORPORATION, PLC , Lincoln House, Lincoln
Place, Dublin 2 , IE

Inventor(s):

ALVAREZ Vernon L, ALVAREZ, Vernon, L. , 187 Rice Drive, Morrisville, PA
19067 , US

O'MAHONY Daniel J, O'MAHONY, Daniel, J. , 75 Avoca Park, Avoca Avenue,
Blackrock, Dublin , IE

LAMBKIN Imelda J, LAMBKIN, Imelda, J. , 9 Station Road, Sutton, Dublin 13
, IE

PATTERSON Catherine A, PATTERSON, Catherine, A. , 3 Grange Crescent,
Pottery Road, Dunlaoghaire, Dublin , IE

SINGLETON Judith, SINGLETON, Judith , Knoll Way, Rocky Way, NJ 08553 , US

BELINKA Benjamin A Jr, BELINKA, Benjamin, A., Jr. , 15 Pelham Road,
Kendall Park, NJ 08824 , US

CARTER John M, CARTER, John, M. , 35 Chicory Lane, Trenton, NJ 08638-1926
, US

CAGNEY Gerard M, CAGNEY, Gerard, M. , 2618 Yale Avenue East, Seattle, WA
98102 , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9851325 A2 19981119

Application: WO 98US10088 19980515 (PCT/WO US9810088)

Priority Application: US 9746595 19970515

Designated States: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GW HU ID
IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI
SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG
KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Filing Language: English

Fulltext Word Count: 72056

English Abstract

This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastro-intestinal tract, thus facilitating its absorption into the systemic system.

French Abstract

L'invention concerne des proteines (par exemple des peptides) capable de faciliter le transport d'un agent actif a travers les tissus gastro-intestinaux d'un humain ou d'un animal. L'invention concerne egalement des derives (par exemple des fragments) et des analogues de ces proteines, ainsi que des sequences nucleotidiques codant ces proteines et ces derives. Les proteines de cette invention sont utiles pour faciliter le transport d'agents actifs depuis le cote lumiere desdits tissus gastro-intestinaux, jusque dans l'appareil cardiovasculaire systemique, et/ou pour diriger des agents actifs vers ces tissus. Ainsi, par exemple, grace a la liaison (par covalence ou non) d'une proteine de cette invention a un medicament administre par voie orale, ce medicament peut etre dirige vers des sites recepteurs specifiques ou des voies de transport connues pour fonctionner dans le tractus gastrointestinal humain, facilitant ainsi son absorption dans le systeme systemique.

9/3,AB/33 (Item 6 from file: 349)

DIALOG(R)File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00598423

DIAGNOSIS AND PROGNOSIS OF GLAUCOMA

DIAGNOSTIC ET PRONOSTIC DU GLAUCOME

Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA , Suite 150, 1320 Harbor Bay Parkway, Alameda,
CA 94502 , US

Inventor(s):

NGUYEN Thai D, NGUYEN, Thai, D. , 17 Central Drive, Mill Valley, CA 94941
, US

POLANSKY Jon R, POLANSKY, Jon, R. , 15 Stanton Way, Mill Valley, CA 94941
, US

HUANG Weidong, HUANG, Weidong , 42 Behr Avenue, San Francisco, CA 94131 ,
US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9844108 A1 19981008

Application: WO 97US5801 19970407 (PCT/WO US9705801)

Priority Application: WO 97US5391 19970401

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE
LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR

IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Publication Language: English
Filing Language: English
Fulltext Word Count: 13867

English Abstract

A glucocorticoid-induced protein, TIGR*, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR* protein, anti-TIGR* antibodies, and TIGR* encoding sequences also provide a diagnostic for glaucoma and its related diseases.

French Abstract

L'invention se rapporte a une proteine induite par glucocorticoides, proteine TIGR* (reponse glucocorticoidique induite par le reseau trabeculaire), qui est produite par des cellules du reseau trabeculaire et qui peut etre utilisee pour diagnostiquer le glaucome. La proteine TIGR*, les anticorps anti-TIGR* et les sequences codant TIGR* assurent egalement le diagnostic du glaucome et des maladies qui y sont associees.

9/3,AB/34 (Item 7 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00598422

DIAGNOSIS AND PROGNOSIS OF GLAUCOMA
DIAGNOSTIC ET PRONOSTIC DU GLAUCOME

Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA , Suite 150, 1320 Harbor Bay Parkway,
Alameda, CA 94502 , US

Inventor(s):

NGUYEN Thai D, NGUYEN, Thai, D. , 17 Central Drive, Mill Valley, CA 94941
, US

POLANSKY Jon R, POLANSKY, Jon, R. , 15 Stanton Way, Mill Valley, CA 94941
, US

HUANG Weidong, HUANG, Weidong , 42 Behr Avenue, San Francisco, CA 94131 ,
US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9844107 A1 19981008

Application: WO 97US5391 19970401 (PCT/WO US9705391)

Priority Application: WO 97US5391 19970401

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE
LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR
IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Filing Language: English

Fulltext Word Count: 13898

English Abstract

A glucocorticoid-induced protein, TIGR*, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR* protein, anti-TIGR* antibodies, and TIGR* encoding sequences also provide a diagnostic for glaucoma and its related diseases.

French Abstract

L'invention se rapporte a une proteine induite par glucocorticoides, proteine TIGR* (reponse glucocorticoidique induite par le reseau trabeculaire), qui est produite par des cellules du reseau trabeculaire et qui peut etre utilisee pour diagnostiquer le glaucome. La proteine TIGR*, les anticorps anti-TIGR* et les sequences codant TIGR* assurent egalement le diagnostic du glaucome et des maladies qui y sont associees.

9/3,AB/35 (Item 8 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00589031

USE OF %MICROPARTICLES% WITH ADSORBED %ANTIGEN% TO STIMULATE IMMUNE RESPONSES

UTILISATION DE MICROPARTICULES CONTENANT UN ANTIGENE ADSORBE DANS LE BUT DE STIMULER LES REPONSES IMMUNITAIRES

Patent Applicant/Assignee:

CHIRON CORPORATION, CHIRON CORPORATION , 4560 Horton Street, Emeryville, CA 94608 , US

Inventor(s):

O'HAGAN Derek, O'HAGAN, Derek , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US

VAN NEST Gary, VAN NEST, Gary , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US

OTT Gary S, OTT, Gary, S. , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US

BARACKMAN John, BARACKMAN, John , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US

KAZZAZ Jina, KAZZAZ, Jina , Chiron Corporation, 4560 Horton Street, R-440, Emeryville, CA 94608 , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9833487 A1 19980806

Application: WO 98US1738 19980129 (PCT/WO US9801738)

Priority Application: US 9736316 19970130; US 9769749 19971216

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Filing Language: English

Fulltext Word Count: 8601

English Abstract

The use of poly(lactide) or poly(lactide-co-glycolide) %microparticles% with adsorbed %antigen% is disclosed. The %microparticles% are useful for enhancing CTL responses to a selected %antigen%.

French Abstract

La presente invention concerne l'utilisation de microparticules de... polylactide ou de polylactide-co-glycolide contenant un antigene adsorbe. Ces microparticules sont utilisees pour stimuler la reponse des cellules T cytotoxiques envers un antigene selectionne.

9/3,AB/36 (Item 9 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00589022

RNA- AND DNA-BASED ACTIVE AGENTS IN NANOPARTICLES
AGENTS ACTIFS A BASE D'ARN ET D'ADN DANS DES NANOPARTICULES

Patent Applicant/Assignee:

GURNY Robert, GURNY, Robert , Universite de Geneve, 30, quai Ernest Ansermet, CH-1211 Geneve , CH

Inventor(s):

GURNY Robert, GURNY, Robert , Universite de Geneve, 30, quai Ernest Ansermet, CH-1211 Geneve , CH

Patent and Priority Information (Country, Number, Date):

Patent: WO 9833478 A2 19980806

Application: WO 98EP420 19980126 (PCT/WO EP9800420)

Priority Application: EP 97101450 19970130

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD
MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US
UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
MR NE SN TD TG

Publication Language: English

Filing Language: English

Fulltext Word Count: 7832

English Abstract

The invention relates to a pharmaceutical composition which is suitable for the incorporation of RNA- and DNA-based active agents in nanoparticles, which are efficient as drug carriers. The active agents may be oligonucleotides or so-called "smart biological bombs". The composition is characterized by the following components: a) the active agent to be incorporated in combination with cationic surfactants within nanoparticles by dispersion methods; b) a pharmaceutically acceptable %biodegradable% synthetic polymer which is suitable for the formation of nanoparticles; c) and, optionally, further pharmaceutically acceptable additives.

French Abstract

L'invention concerne une composition pharmaceutique qui peut être incorporée dans des agents actifs à base d'ARN et d'ADN, dans des nanoparticules, qui constituent des vecteurs de médicaments efficaces. Ces agents actifs peuvent être des oligonucleotides ou des agents dits "bombes biologiques intelligentes". Cette composition se caractérise par les composants suivants: (a) l'agent actif est incorporé en combinaison avec des tensioactifs cationiques dans des nanoparticules par des procédés de dispersion; (b) un polymère de synthèse %biodegradable% pharmaceutiquement acceptable qui convient pour la formation de nanoparticules; et (c) éventuellement, d'autres additifs pharmaceutiquement acceptables.

9/3,AB/37 (Item 10 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00588278

METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GLAUCOMA AND RELATED DISORDERS

PROCEDES DE DIAGNOSTIC, DE PRONOSTIC ET DE TRAITEMENT DU GLAUCOME ET DE TROUBLES ASSOCIES

Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA, 22nd floor, 300 Lakeside Drive, Oakland, CA
94612-3550, US

Inventor(s):

NGUYEN Thai D, NGUYEN, Thai, D., 17 Central Drive, Mill Valley, CA 94941,
US

POLANSKY Jon R, POLANSKY, Jon, R., 15 Stanton Way, Mill Valley, CA 94941,
US

CHEN Pu, CHEN, Pu, 6090 Darleen Court, Rohnert Park, CA 94928, US

CHEN Hua, CHEN, Hua, 371 Twentieth Street, San Francisco, CA 94121, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9832850 A1 19980730

Application: WO 98US468 19980109 (PCT/WO US9800468)

Priority Application: US 97791154 19970128

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD
MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ
VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR
NE SN TD TG

English Abstract

The nucleic acid upstream of the TIGR protein encoding sequence can be used to diagnose glaucoma. Polymorphisms, base substitutions, base additions located with the upstream and within TIGR exons can also be used to diagnose glaucoma. In addition, polymorphisms, base substitutions, base additions located with the upstream and within TIGR exons can also be used to prognose glaucoma.

French Abstract

On peut utiliser l'acide nucleique situe en amont de la sequence codant la proteine TIGR afin de diagnostiquer le glaucome. On peut egalement utiliser des polymorphismes, des substitutions de bases, des additions de bases situees au moyen des exons amont et a l'interieur des exons TIGR afin de diagnostiquer le glaucome. De plus, on peut egalement utiliser des polymorphismes, des substitutions de bases, des additions de bases situees au moyen des exons amont et a l'interieur des exons TIGR afin de pronostiquer le glaucome.

9/3,AB/38 (Item 11 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00587014

THERAPEUTIC TREATMENT AND PREVENTION OF INFECTIONS WITH A BIOACTIVE MATERIAL ENCAPSULATED WITHIN A %BIODEGRADABLE%-BIOCOMPATIBLE POLYMERIC MATRIX

TRAITEMENT THERAPEUTIQUE ET PREVENTION D'INFECTIONS A L'AIDE DE SUBSTANCES BIOACTIVES ENCAPSULEES DANS UNE MATRICE POLYMERE %BIODEGRADABLE%-BIOCOMPATIBLE

Patent Applicant/Assignee:

UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE ARMY,
UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE ARMY ,
Intellectual Property Law Division, OTJAG, DA, Suite 713, 901 North
Stuart Street, Arlington, VA 22203-1837 , US

Inventor(s):

SETTERSTROM Jean A, SETTERSTROM, Jean, A. , 700 Hampton Trace Lane,
Alpharetta, GA 30201 , US
VAN HAMONT John E, VAN HAMONT, John, E. , 160A Gardiner Loop, West Point,
NY 10996 , US
REID Robert H, REID, Robert, H. , 10807 McComas Court, Kensington, MD
20895 , US
JACOB Elliot, JACOB, Elliot , 11529 Dafford Lane, Silver Spring, MD 20902
, US
JEYANTHI Ramasubbu, JEYANTHI, Ramasubbu , 9725 Clocktower Lane &301,
Columbia, MD 21046 , US
BOEDEKER Edgar C, BOEDEKER, Edgar, C. , 7505 Bybrook Lane, Chevy Chase,
MD 20815 , US
MCQUEEN Charles E, MCQUEEN, Charles, E. , 16805 Ethelwood Terrace, Olney,
MD 20832 , US
TICE Thomas R, TICE, Thomas, R. , 1915 Forest River Court, Birmingham, AL
35244 , US
ROBERTS F Donald, ROBERTS, F., Donald , 2 Bridge Path Circle, Dover, MA
02030 , US
FRIDEN Phil, FRIDEN, Phil , 32 Washington Street, Bedford, MA 01730 , US

Patent and Priority Information (Country, Number, Date):

Patent: WO 9832427 A1 19980730
Application: WO 98US1556 19980127 (PCT/WO US9801556)
Priority Application: US 97789734 19970127

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN
MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU

ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN
TD TG

Publication Language: English
Filing Language: English
Fulltext Word Count: 63830

English Abstract

Novel burst-free, sustained release biocompatible and %biodegradable%
%microcapsules% which can be programmed to release their active core for
variable durations ranging from 1-100 days in an aqueous physiological
environment. The %microcapsules% are comprised of a core of polypeptide
or other biologically active agent encapsulated in a matrix of
poly(lactide/glycolide) copolymer, which may contain a pharmaceutically
acceptable adjuvant, as a blend of uncapped free carboxyl end group and
end-capped forms ranging in ratios from 100/0 to 1/99.

French Abstract

Cette invention se rapporte a de nouvelles %microcapsules% biocompatibles
et biodegradables a liberation prolongee, sans pic, qui peuvent etre
programmees pour liberer leur noyau actif pour des durees variables
allant de 1 a 100 jours dans un milieu physiologique aqueux. Ces
%microcapsules% sont constituees par un noyau de polypeptides ou d'un
autre agent biologiquement actif encapsule dans une matrice de
copolymeres de poly(lactide/glycolide), qui peut contenir un adjuvant
acceptable sur le plan pharmaceutique, se presentant sous la forme d'un
melange de groupes terminaux a carboxyle libre sans coiffe et de formes a
coiffe terminale selon des rapports compris entre 100/0 et 1/99.

9/3,AB/39 (Item 12 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00583915

METHOD OF PRODUCING A SUSTAINED-RELEASE PREPARATION
PROCEDE DE PRODUCTION D'UNE PREPARATION A LIBERATION PROLONGEE
Patent Applicant/Assignee:

TAKEDA CHEMICAL INDUSTRIES LTD, TAKEDA CHEMICAL INDUSTRIES, LTD. , 1-1,
Doshomachi 4-chome, Chuo- ku, Osaka-shi, Osaka 541 , JP

Inventor(s):

YAMAGATA Yutaka, YAMAGATA, Yutaka , 1-8-207, Doshodai 1-chome, Suma-ku,
Kobe-shi, Hyogo 654 , JP
MISAKI Masafumi, MISAKI, Masafumi , 4-41-103, Hibarigaoka 2-chome,
Takarazuka-shi, Hyogo 665 , JP
IWASA Susumu, IWASA, Susumu , 21-2, Ohsumigaoka 1-chome, Kyotanabe-shi,
Kyoto 610-03 , JP

Patent and Priority Information (Country, Number, Date):

Patent: WO 9827980 A2 19980702
Application: WO 97JP4671 19971218 (PCT/WO JP9704671)
Priority Application: JP 96342046 19961220

Designated States: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL
IS KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ
TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU
TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
CM GA GN ML MR NE SN TD TG

Publication Language: English
Filing Language: English
Fulltext Word Count: 9834

English Abstract

A method of producing sustained-release %microcapsules% which comprises
dispersing a physiologically active polypeptide into a solution of a
%biodegradable% polymer and zinc oxide in an organic solvent, followed by
removing the organic solvent; which provides a sustained- release
preparation showing a high entrapment ratio of the physiologically active

groupe II (tel que CaCl_2) pour former une suspension de microspheres de polyphosphazene. Les microspheres de polyphosphazene sont ensuite recuperees de la suspension. Ce procede permet d'obtenir des rendements eleves de production de microspheres dont la repartition des dimensions est controlee.

t s9/3,ab/41-65

>>>No matching display code(s) found in file(s): 65, 342, 345, 764

9/3,AB/41 (Item 14 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00542385

ADMINISTRATION OF HISTAMINE FOR THERAPEUTIC PURPOSES

ADMINISTRATION D'HISTAMINE A DES FINS THERAPEUTIQUES

Patent Applicant/Assignee:

MAXIM PHARMACEUTICALS INC, MAXIM PHARMACEUTICALS, INC. , 3099 Science
Park Road, San Diego, CA 92121 , US

Inventor(s):

HELLSTRAND Kristoffer, HELLSTRAND, Kristoffer , Brodragatan 19, S­412
74 Goteborg , SE

HERMODSSON Svante, HERMODSSON, Svante , Bergsbogatan 2, S­431 38
Molndal , SE

Patent and Priority Information (Country, Number, Date):

Patent: WO 9742968 A2 19971120

Application: WO 97US8001 19970512 (PCT/WO US9708001)

Priority Application: US 96649121 19960514; US 96767338 19961216

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN
MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU GH KE
LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR
IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Filing Language: English

Fulltext Word Count: 9998

English Abstract

Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing the cytotoxicity of cytotoxic effector cells. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance the cytotoxicity of cytotoxic effector cells, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.

French Abstract

L'invention a trait a des procedes, permettant d'obtenir des taux stables bienfaisants d'histamine circulante, utilisables dans des techniques de renforcement de la cytotoxicite de cellules effectrices cytotoxiques. On obtient, au titre de ces procedes, un taux bienfaisant d'histamine circulante, et l'on administre un agent dont l'aptitude a renforcer la cytotoxicite naturelle d'une cellule lytique est accrue par l'histamine. Dans une variante, on obtient, chez des sujets soignes par chimiotherapie ou suivant un traitement antiviral, des taux stables bienfaisants d'histamine circulante. Cette invention peut egalement servir dans le cas de traitement combinant l'histamine, des agents renforçant la cytotoxicite de cellules effectrices cytotoxiques ainsi que des agents entrant dans une chimiotherapie. L'invention porte egalement sur l'optimalisation de l'administration d'histamine et de substances

provoquant la liberation d'histamine endogene.

9/3,AB/42 (Item 15 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00535523

SUSTAINED­RELEASE PREPARATION AND ITS PRODUCTION
PREPARATION A LIBERATION PROLONGEE ET PRODUCTION DE CETTE PREPARATION
Patent Applicant/Assignee:

TAKEDA CHEMICAL INDUSTRIES LTD, TAKEDA CHEMICAL INDUSTRIES, LTD. ,
1­l, Doshomachi 4­chome, Chuo­ku, Osaka­shi, Osaka 541
, JP

Inventor(s):

TAKADA Shigeyuki, TAKADA, Shigeyuki , 8­l­319, Ohwakidai,
Kita­ku, Kobe­shi, Hyogo 651­l1 , JP
KUROKAWA Tomofumi, KUROKAWA, Tomofumi , 50­A­508, Wakaba
2­chome, Inagawa­cho, Kawabe­gun, Hyogo 666­02 , JP
IWASA Susumu, IWASA, Susumu , 21­2, Ohsumigaoka 1­chome,
Tanabe­cho, Tsuzuki­gun, Kyoto 610­03 , JP

Patent and Priority Information (Country, Number, Date):

Patent: WO 9735563 A2 19971002

Application: WO 97JP1041 19970327 (PCT/WO JP9701041)

Priority Application: JP 9673016 19960328

Designated States: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL IS
KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR
TT UA US UZ VN YU GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE
CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
MR NE SN TD TG

Publication Language: English

Filing Language: English

Fulltext Word Count: 10599

English Abstract

Disclosed is a sustained­release preparation characterized in that it
is produced by dispersing in an oil phase a rapidly dried product
containing a bioactive polypeptide and a surfactant, and subsequent
shaping, and a method of its production.

French Abstract

Cette invention concerne une preparation a liberation prolongee, laquelle
est obtenue en dispersant, dans une phase d'huile, un produit seche
rapidement et contenant un polypeptide bioactif ainsi qu'un tensioactif,
ceci avant de proceder a la mise en forme. Cette invention concerne
egalement un procede de production de cette preparation.

9/3,AB/43 (Item 16 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00504345

MODULATORS OF EXPRESSION AND FUNCTION OF LRP IN ALZHEIMER'S DISEASE
MODULATEURS D'EXPRESSION ET DE FONCTION DE LA PROTEINE ASSOCIEE AU
RECEPTEUR DE LA LIPOPROTEINE BASSE DENSITE (LRP) DANS LA MALADIE
D'ALZHEIMER

Patent Applicant/Assignee:

THE AMERICAN NATIONAL RED CROSS
THE GENERAL HOSPITAL CORPORATION

Inventor(s):

STRICKLAND Dudley K
HYMAN Bradley T
KOUNNAS Maria Z
MOIR Robert D
TANZI Rudolph E

Patent and Priority Information (Country, Number, Date):

Patent: WO 9704794 A1 19970213
Application: WO 96US12686 19960729 (PCT/WO US9612686)
Priority Application: US 951600 19950727; US 951653 19950728
Designated States: CA JP MX AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT
SE
Publication Language: English
Fulltext Word Count: 11475

English Abstract

The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid 'beta'-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members of the low density lipoprotein receptor family.

Japanese Abstract

La presente invention se rapporte generalement au traitement, au diagnostic et la prophylaxie de la maladie d'Alzheimer. Plus particulierement, l'invention se rapporte a des procedes et a des compositions pour la prevention de l'endocytose et de l'internalisation cellulaire de la proteine membranaire integrale dite proteine precurseur 'beta' amyloide (APP) et de son catabolisme ulterieur en bloquant ou en interferant avec l'association ou la liaison de l'APP avec des membres de la famille de recepteurs de la lipoproteine basse densite.

9/3,AB/44 (Item 17 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00500819

METHOD OF PRODUCING SUSTAINED-RELEASE PREPARATION
PRODUCTION DE PREPARATIONS A LIBERATION PROLONGEE

Patent Applicant/Assignee:

TAKEDA CHEMICAL INDUSTRIES LTD

OKAMOTO Kayoko

YAMAGATA Yutaka

IGARI Yasutaka

MISAKI Masafumi

Inventor(s):

OKAMOTO Kayoko

YAMAGATA Yutaka

IGARI Yasutaka

MISAKI Masafumi

Patent and Priority Information (Country, Number, Date):

Patent: WO 9701331 A2-A3 19970116

Application: WO 96JP1770 19960626 (PCT/WO JP9601770)

Priority Application: JP 95161204 19950627; JP 96102403 19960424

Designated States: AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS KG KR KZ
LK LR LT LV MD MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN KE
LS MW SD SZ UG BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT
LU MC NL PT SE CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 10798

English Abstract

This invention provides a sustained-release preparation comprising a %biodegradable% polymer metal salt and bioactive polypeptide, with enhanced entrapment of the bioactive polypeptides, a suppression of initial burst, and a constant long-term release of the bioactive polypeptides.

Japanese Abstract

Cette invention concerne une preparation a liberation prolongee comprenant un sel metallique de polymere %biodegradable% et un polypeptide bioactif, avec amelioration de piegeage des polypeptides bioactifs, suppression de la bouffee de depart et liberation constante a long terme des polypeptides bioactifs.

9/3,AB/45 (Item 18 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00444380

NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE
NOUVELLES COMPOSITIONS CIBLEES, DESTINEES A UNE UTILISATION DIAGNOSTIQUE ET
THERAPEUTIQUE

Patent Applicant/Assignee:
IMARx PHARMACEUTICAL CORP
UNGER Evan C
SHEN Dekang
WU Guanli

Inventor(s):
UNGER Evan C
SHEN Dekang
WU Guanli

Patent and Priority Information (Country, Number, Date):

Patent: WO 9640285 A1 19961219

Application: WO 96US9938 19960606 (PCT/WO US9609938)

Priority Application: US 95497684 19950607; US 96640464 19960501

Designated States: AU CA CN JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC
NL PT SE

Publication Language: English

Fulltext Word Count: 60067

English Abstract

Novel targeted compositions which may be used for diagnostic and therapeutic use. The compositions may comprise a lipid, a protein or a polymer and a gas, in combination with a targeting ligand. The targeting ligand targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIb/IIIa receptor. The contrast media can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.

Japanese Abstract

Ces nouvelles compositions cibles, que l'on peut utiliser a des fins diagnostiques et therapeutiques, peuvent comprendre un lipide, une proteine ou un polymere, ainsi qu'un gaz, en combinaison avec un ligand de ciblage. Ce ligand cible des tissus, des cellules ou des recepteurs, notamment des cellules myocardiques, endotheliales, epitheliales, tumorales, ainsi que le recepteur de la glycoproteine GPIIb/IIIa. On peut utiliser ces substances de contraste conjointement avec l'imagerie diagnostique, telle que l'echographie, ainsi qu'avec des applications therapeutiques, telles que l'ultrasonotherapie.

9/3,AB/46 (Item 19 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00444205

TREATMENT OF A TRABECULAR MESHWORK WHOSE CELLS ARE SUBJECT OT INHIBITION OF
CELL DIVISION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
TRAITEMENT PAR ANTI-INFLAMMATOIRES NON STEROIDIENS DE TISSUS TRABECULAIRES
DONT LES CELLULES SONT SUJETTES A L'INHIBITION DE LA DIVISION
CELLULAIRE

Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s):

POLANSKY Jon R
BLOOM Ernest
FAUSS Donald J

Patent and Priority Information (Country, Number, Date):

Patent: WO 9640103 A1 19961219
Application: WO 96US7401 19960521 (PCT/WO US9607401)
Priority Application: US 95486255 19950607

Designated States: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB
GE HU IS JP KE KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO
RU SD SE SG SI TM TR TT UA UG UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD
RU TJ TM AT BE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN ML MR NE TG

Publication Language: English

Fulltext Word Count: 9294

English Abstract

The invention concerns the recognition that certain non-steroidal anti-inflammatory agents can overcome or ameliorate limitations on trabecular meshwork cell division produced by environmental stresses (e. g., oxidative or phagocytic injury, or glucocorticoid exposure), and thus can be used to prevent or treat loss of trabecular cells found in certain forms of glaucoma and in normal aging. The use of such non-steroidal anti-inflammatory agents can ameliorate the severity, or prevent glaucoma.

Japanese Abstract

Cette invention concerne la capacite de certains agents anti-inflammatoires non steroïdiens de supprimer ou de reduire les limitations entravant la division cellulaire se produisant dans un tissu trabeculaire a cause de contraintes du milieu environnant (par exemple, blessures oxydantes ou phagocytaires, ou exposition a des glucocorticoides). Ces agents peuvent ainsi etre utilises afin de prevenir ou de traiter la perte de cellules trabeculaires que l'on rencontre dans certaines formes de glaucomes ou lors du processus normal de vieillissement. L'utilisation de tels agents anti-inflammatoires non steroïdiens permet de limiter la gravite des glaucomes ou de les prevenir.

9/3,AB/47 (Item 20 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00444204

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FOR THE CYTO-PROTECTION OF THE
TRABECULAR MESHWORK
MEDICAMENTS NON STEROIDIENS ANTI-INFLAMMATOIRES DESTINES A LA
CYTOPROTECTION DE TISSUS TRABECULAIRES

Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor(s):

POLANSKY Jon R
BLOOM Ernest
FAUSS Donald J

Patent and Priority Information (Country, Number, Date):

Patent: WO 9640102 A1 19961219
Application: WO 96US7340 19960521 (PCT/WO US9607340)
Priority Application: US 95479185 19950607

Designated States: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB
GE HU IS JP KE KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO
RU SD SE SG SI TM TR TT UA UG UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD
RU TJ TM AT BE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN ML MR NE TG

Publication Language: English

Fulltext Word Count: 9726

English Abstract

The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury of the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells. Such treatment can ameliorate the severity or prevent glaucoma.

Japanese Abstract

Cette invention concerne la capacite de certains agents non steroïdiens et anti-inflammatoires a produire des effets cytoprotecteurs sur des cellules trabeculaires. Ces medicaments peuvent etre employes afin de prevenir des lesions des cellules, et de traiter la perte de cellules trabeculaires engendree par des lesions de type oxydante ou autre de ces cellules. Un tel traitement permet de limiter la gravite des glaucomes ou de les prevenir.

9/3,AB/48 (Item 21 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00418796

METHODS FOR THE DIAGNOSIS OF GLAUCOMA
PROCEDES DE DIAGNOSTIC DU GLAUCOME

Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor(s):

NGUYEN Thai D
POLANSKY Jon R
HUANG Weidong

Patent and Priority Information (Country, Number, Date):

Patent: WO 9614411 A1 19960517
Application: WO 95US14024 19951027 (PCT/WO US9514024)
Priority Application: US 94336235 19941103

Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
IS JP KE KG KP LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD
SE SG SI SK TJ UA UG UZ VN KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR
IE IT LU MC NL BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 16187

English Abstract

A glucocorticoid-induced protein, TIGR, that is produced by cells of the trabecular meshwork can be used to diagnose glaucoma. The TIGR protein, anti-TIGR antibodies, and TIGR encoding sequences also provide a diagnostic for glaucoma and its related diseases.

Japanese Abstract

La presente invention concerne une proteine induite par un glucocorticoide, la TIGR, produite par les cellules du maillage trabeculaire, qui peut servir a diagnostiquer un glaucome. Ladite proteine TIGR, les anticorps anti-TIGR, ainsi que les sequences d'ADN codant pour la proteine TIGR offrent egalement un moyen de diagnostic du glaucome et des maladies associees a celui-ci.

9/3,AB/49 (Item 22 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00417444

SENESCENT CELL-DERIVED INHIBITORS OF DNA SYNTHESIS
INHIBITEURS DE SYNTHESE D'ADN PRODUITS DANS DES CELLULES SENESCENTES

Patent Applicant/Assignee:

BAYLOR COLLEGE OF MEDECINE
SENNES DRUG INNOVATIONS INC

Inventor(s):

SMITH James R
DRUTZ David G
WILSON Deborah R
ZUMSTEIN Louis A

Patent and Priority Information (Country, Number, Date):

Patent: WO 9612506 A1 19960502
Application: WO 95US13766 19951024 (PCT/WO US9513766)
Priority Application: US 94327874 19941024; WO 95US6451 19950523; US
95524218 19950906

Designated States: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 51728

English Abstract

The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.

Japanese Abstract

L'utilisation de formulations liposomiques, en particulier, des formulations de lipides neutres et positivement charges facilite le captage cellulaire de molecules d'inhibiteurs produits dans des cellules senescentes (SDI). La transcription et/ou l'expression de molecules d'acide nucleique codant SDI-1 est facilitee par des produits de recombinaison contenant des regions intervenantes non traduites.

9/3,AB/50 (Item 23 from file: 349)

DIALOG(R) File 349:PCT Fulltext

(c) 2001 WIPO/MicroPat. All rts. reserv.

00412501

SYNTHETIC GANGLIOSIDE DERIVATIVES

DERIVES SYNTHETIQUES DE GANGLIOSIDES

Patent Applicant/Assignee:

LADISCH Stephan

Inventor(s):

LADISCH Stephan

HASEGAWA Akira

Patent and Priority Information (Country, Number, Date):

Patent: WO 9608257 A1 19960321
Application: WO 95US11670 19950914 (PCT/WO US9511670)
Priority Application: US 94305832 19940914

Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU IS

JP KE KG KP KR LU LV MD MG MN MW NO NZ PL PT RO RU SD SE SG SI SK TJ TM

TT UA UG UZ VN SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

BF BJ CF CG CI GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 9195

English Abstract

Compositions of matter comprising glycosphingolipids useful for suppressing an immune response having formula (I) wherein x is (a) or (b) or H; wherein Y is (c) or H; wherein m is 10 to 20; and wherein n is 1 to 14. Also presented are methods for suppressing an immune response in an animal employing glycosphingolipids as shown above. Synthetic gangliosides having artificial hydrophobic anchors, useful for suppressing an immune response having formula (II) wherein A is a carbohydrate moiety of a ganglioside, n is 5 to 20 and m is 5 to 20. Also presented are methods for suppressing an immune response in an animal and compositions of matter employing synthetic gangliosides having artificial

hydrophobic anchors, as shown above. Simplified carbohydrate moiety-gangliosides, useful for suppressing an immune response according to formula (III) wherein B is a ceramide moiety of a ganglioside. Also presented are methods for suppressing an immune response in an animal and compositions of matter employing simplified carbohydrate moiety-ganglioside as shown above.

Japanese Abstract

Compositions comprenant des glycosphingolipides permettant de supprimer une reponse immunitaire et repondant a la formule (I) dans laquelle x represente (a) ou (b) ou H; Y est (c) ou H; m est compris entre 10 et 20 inclus et n est compris entre 1 et 14 inclus. Des procedes de suppression d'une reponse immunitaire chez l'animal a l'aide desdits glycosphingolipides sont egalement decrits. Des gangliosides synthetiques ayant des supports d'adherence hydrophobes artificiels, permettant de supprimer une reponse immunitaire, repondant a la formule (II) dans laquelle A est une fraction hydrate de carbone d'un ganglioside, n est compris entre 5 et 20 inclus et m est compris entre 5 et 20 inclus sont encore decrits. La presente invention concerne de surcroit des procedes de suppression de la reponse immunitaire chez un animal et des compositions a cet effet contenant des gangliosides synthetiques contenant des supports d'adherence hydrophobes artificiels decrits ci-dessus. Elle concerne aussi des gangliosides a fraction hydrate de carbone simplifies permettant de supprimer une reponse immunitaire, et repondant a la formule (III) dans laquelle B est une fraction ceramide d'un ganglioside. Elle concerne enfin des procedes de suppression de la reponse immunitaire chez un animal et des compositions contenant des gangliosides a fraction hydrate de carbone simplifies decrits ci-dessus.

9/3,AB/51 (Item 24 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00408311

SOLID DELIVERY SYSTEMS FOR CONTROLLED RELEASE OF MOLECULES INCORPORATED THEREIN AND METHODS OF MAKING SAME
SYSTEMES D'ADMINISTRATION DE SUBSTANCES SOLIDES, POUR LA LIBERATION CONTROLEE DE MOLECULES INCORPOREES DANS CES SUBSTANCES ET PROCEDES DE FABRICATION DE CES SYSTEMES

Patent Applicant/Assignee:

QUADRANT HOLDINGS CAMBRIDGE LIMITED
ROSER Bruce Joseph
COLACO Camilo
JERROW Mohamed Abdel Zahra
BLAIR Julian Alexander
KAMPINGA Jaap
WARDELL James Lewis
DUFFY John Alistair

Inventor(s):

ROSER Bruce Joseph
COLACO Camilo
JERROW Mohamed Abdel Zahra
BLAIR Julian Alexander
KAMPINGA Jaap
WARDELL James Lewis
DUFFY John Alistair

Patent and Priority Information (Country, Number, Date):

Patent: WO 9603978 A1 19960215
Application: WO 95GB1861 19950804 (PCT/WO GB9501861)
Priority Application: GB 9415810 19940804; US 94349029 19941202

Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
IS JP KE KG KP LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG
SI SK TJ TM TT US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT
LU MC NL PT SE CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

English Abstract

The present invention encompasses solid dose delivery systems for administration of guest substances. Preferred delivery systems are suitable for delivery of bioactive materials to subcutaneous and intradermal, intramuscular, intravenous tissue, the delivery system being sized and shaped for penetrating the epidermis. The delivery systems comprise a vitreous vehicle loaded with the guest substance and capable of releasing the guest substance in situ at various controlled rates. The present invention further includes methods of making and using the solid dose delivery systems.

Japanese Abstract

Cette invention se rapporte a des systemes d'apport de doses de substances solides, qui servent a l'administration de substances hotes incorporees dans ces doses. Les systemes d'administration preferes de cette invention se pretent a l'apport de matieres bioactives dans des tissus intraveineux, intramusculaires, sous-cutanes et intradermiques, la taille et la forme de ce systeme d'apport etant concues pour lui permettre de penetrer dans l'epiderme. Ces systemes d'apport comprennent un excipient vitreux charge de la substance hote et capable de liberer cette substance hote in situ a divers taux controles. Cette invention se rapporte en outre a des procedes pour fabriquer et utiliser ces systemes d'administration de doses de substances solides.

9/3,AB/52 (Item 25 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00405237

TARGETED GENE DELIVERY SYSTEM
SYSTEME DE TRANSPORT DE GENE CIBLE

Patent Applicant/Assignee:

THE JOHNS HOPKINS UNIVERSITY

Inventor(s):

TRUONG Vu L
AUGUST Thomas
LEONG Kam W

Patent and Priority Information (Country, Number, Date):

Patent: WO 9600295 A1 19960104
Application: WO 95US7857 19950623 (PCT/WO US9507857)
Priority Application: US 94265966 19940627

Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
IS JP KE KG KP LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG
SI SK TJ TM TT UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU
MC NL PT SE BF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English
Fulltext Word Count: 4147

English Abstract

A target-specific gene delivery system is made of enzymatically degradable gelatin and nucleic acids (DNA or RNA) %microparticles% with a linking moiety or a targeting ligand attached to the surface. The delivery system can be made by a simple method. Targeting ligands can be attached to the %microparticle% directly or via a linking moiety. The linkage design allows the attachment of any molecule onto the %microparticle% surface including antibodies, cell adhesion molecules, hormones and other cell-specific ligands.

Japanese Abstract

Systeme de transport d'un gene specifique d'une cible, compose de microparticules de gelatine degradable enzymatiquement et d'acides nucleiques (ADN ou ARN) comportant une fraction de liaison ou un ligand de ciblage lies a la surface. Ce systeme de transport peut etre realise

par un procede simple. Des ligands de ciblage peuvent etre fixes sur une microparticule directement ou par l'intermediaire d'une fraction de liaison. La structure de la liaison permet de fixer toute molecule sur la surface d'une microparticule, y compris des anticorps, des molecules d'adherence cellulaire, des hormones et d'autres ligands a specificite cellulaire.

9/3,AB/53 (Item 26 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00397013

AQUEOUS SOLVENT ENCAPSULATION METHOD, APPARATUS AND %MICROCAPSULES%
PROCEDE D'ENCAPSULATION PAR SOLVANT AQUEUX, APPAREIL ET %MICROCAPSULES%
Patent Applicant/Assignee:

TEMPLE UNIVERSITY
CHILDREN'S HOSPITAL OF PHILADELPHIA
CLARK Fred H
OFFIT Paul A
MOSER Charlotte A
SPEAKER Tully J

Inventor(s):

CLARK Fred H
OFFIT Paul A
MOSER Charlotte A
SPEAKER Tully J

Patent and Priority Information (Country, Number, Date):

Patent: WO 9528227 A1 19951026
Application: WO 95US4711 19950417 (PCT/WO US9504711)
Priority Application: US 94228481 19940415; US 94229283 19940418; US
94229520 19940418

Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
IS JP KE KG KP LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG
SI SK TJ TM TT US US US UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR
IE IT LU MC NL BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 20950

English Abstract

A %microcapsule% substantially free from non-aqueous contaminants comprising an aqueous core surrounded by a capsular wall, the capsular wall being the reaction product of a selected water soluble anionic polymer or salt thereof with a selected water soluble amine or salt thereof, the selected anionic polymer and amine having the property that, when droplets of an aqueous solution of the selected polymer are introduced into an aqueous solution of the selected amine, stable %microcapsules% of the amine salt of the anionic polymer are formed. The aqueous core of the %microcapsule% may contain any of various active ingredients, including immunogenic agents such as rotavirus. A method and apparatus for making the %microcapsules%, including %microcapsules% comprising active agents, as well as their method of use, are also disclosed.

Japanese Abstract

La presente invention concerne une %microcapsule% essentiellement exempte de contaminants non aqueux et se composant d'un noyau aqueux entoure d'une paroi capsulaire. Ladite paroi capsulaire est le produit de reaction d'un polymere anionique hydrosoluble selectionne, ou de l'un de ses sels, avec une amine hydrosoluble selectionnee, ou l'un de ses sels. Le polymere anionique selectionne et l'amine sont caracterises par la formation de %microcapsules% stables du sel d'amine du polymere anionique lors de l'introduction des gouttelettes d'une solution aqueuse du polymere selectionne dans une solution aqueuse de l'amine selectionnee. Le noyau aqueux de la %microcapsule% peut contenir l'un quelconque des principe actifs, y compris des agents immunogenes tels qu'un rotavirus.

L'invention concerne egalement un appareil et un procede de fabrication des %microcapsules%, y compris des %microcapsules% renfermant des agents actifs, ainsi que leurs procedes d'utilisation.

9/3,AB/54 (Item 27 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00385224

CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCES FOR IMMUNOTHERAPY
LIBERATION CONTROLEE DE SUBSTANCES PHARMACEUTIQUEMENT ACTIVES POUR
L'IMMUNOTHERAPIE

Patent Applicant/Assignee:

JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Inventor(s):

PARDOLL Drew

AZHARI Rosa

LEONG Kam W

GOLUMBEK Paul

JAFFEE Elizabeth

LEVITSKY Hyam

LAZENBY Audrey

Patent and Priority Information (Country, Number, Date):

Patent: WO 9516464 A1 19950622

Application: WO 94US14642 19941213 (PCT/WO US9414642)

Priority Application: US 93167562 19931214

Designated States: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 7805

English Abstract

A method of stimulating a systemic immune response to a tumor cell or %antigen% associated with a pathogen by administering a mixture of a controlled release vehicle containing an immunopotentiating agent and %antigen% is described.

Japanese Abstract

L'invention concerne un procede pour stimuler une reponse immunitaire systematique sur une cellule tumorale ou un antigene associe a un pathogene. Ce procede consiste a administrer un melange d'un vehicule a liberation controlee contenant un agent renforçant l'immunité et un antigene.

9/3,AB/55 (Item 28 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00382576

BIOCOMPATIBLE OCULAR IMPLANTS

IMPLANTS OCULAIRES BIOCOPATIBLES

Patent Applicant/Assignee:

OCULEX PHARMACEUTICALS INC

Inventor(s):

WONG Vernon G

KOCHINKE Frank

Patent and Priority Information (Country, Number, Date):

Patent: WO 9513765 A1 19950526

Application: WO 94US12898 19941109 (PCT/WO US9412898)

Priority Application: US 93153184 19931115

Designated States: AU CA CN JP KR RU AT BE CH DE DK ES FR GB GR IE IT LU MC

NL PT SE

Publication Language: English

Fulltext Word Count: 9405

POWELL Michael Frank
Patent and Priority Information (Country, Number, Date):
Patent: WO 9511008 A2-A3 19950427
Application: WO 94US11674 19941013 (PCT/WO US9411674)
Priority Application: US 93141341 19931022; US 93143332 19931025
Designated States: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Fulltext Word Count: 16058

English Abstract

Methods and compositions are provided for the encapsulation of adjuvants in PLGA microspheres for use as vaccines. Mixtures of microspheres are provided which release adjuvant at desired intervals to provide boosts with adjuvant.

Japanese Abstract

L'invention concerne des procedes et des compositions s'utilisant dans la microencapsulation d'adjuvants dans des microspheres de poly(D-L-lactide-coglycolide) (PLGA) utilisees comme vaccins. L'invention concerne en outre des melanges de microspheres qui liberent lesdits adjuvants a intervalles voulus pour produire des effets de rappel.

9/3,AB/58 (Item 31 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00375611

SENESCENT CELL-DERIVED INHIBITORS OF DNA SYNTHESIS
INHIBITEURS DE SYNTHESE D'ADN DERIVES DE CELLULES SENESCENTES

Patent Applicant/Assignee:

BAYLOR COLLEGE OF MEDICINE

SMITH James R

Inventor(s):

SMITH James R

Patent and Priority Information (Country, Number, Date):

Patent: WO 9506415 A1 19950309

Application: WO 94US9700 19940826 (PCT/WO US9409700)

Priority Application: US 93113372 19930830; US 93153564 19931117; US 94160814 19940103; US 94203535 19940225; US 94229420 19940415; US 94268439 19940630; US 94274535 19940713

Designated States: AU CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 44781

English Abstract

An expression vector cDNA library derived from senescent cells has been used to isolate cDNA clones that encode inhibitors of DNA synthesis. Such inhibitors play a role in cellular senescence, aging and neoplasia. Antisense nucleic acids reduce the inhibition of DNA synthesis. The invention concerns such molecules, their inhibitors, antagonists and derivatives. The invention also concerns diagnostic, therapeutic and in vitro uses for all such agents.

Japanese Abstract

Une banque d'ADNc de vecteur d'expression derivee de cellules senescentes a ete utilisee pour isoler des clones d'ADNc codant des inhibiteurs de la synthese d'ADN. De tels inhibiteurs jouent un role dans la senescence, le vieillissement et la neoplasie cellulaires. Des acides nucleiques antisens reduisent l'inhibition de la synthese d'ADN. L'invention se rapporte a de telles molecules ainsi qu'a leurs inhibiteurs, antagonistes et derives. L'invention se rapporte egalement aux utilisations diagnostiques, therapeutiques et in vitro de tous ces agents.

9/3,AB/59 (Item 32 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00363196

ENCAPSULATION OF NUCLEIC ACIDS WITH CONJUGATES THAT FACILITATE AND TARGET
CELLULAR UPTAKE AND GENE EXPRESSION
ENCAPSULATION D'ACIDES NUCLEIQUES AVEC DES CONJUGUES QUI FACILITENT ET
CIBLENT L'ABSORPTION CELLULAIRE ET L'EXPRESSION GENIQUE

Patent Applicant/Assignee:

MEDISORB TECHNOLOGIES INTERNATIONAL LP

Inventor(s):

McELLIGOTT Sandra Gertrude

AMOS Michael David

Patent and Priority Information (Country, Number, Date):

Patent: WO 9423738 A1 19941027

Application: WO 94US4239 19940419 (PCT/WO US9404239)

Priority Application: US 9347536 19930419

Designated States: AU CA JP NZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT
SE

Publication Language: English

Fulltext Word Count: 13082

English Abstract

This invention is a method for encapsulating nucleic acids linked to or co-existing with other molecules that facilitate the uptake and integration of genetic material into living cells by means of slow-release of DNA/RNA or oligonucleotides combined with cell surface ligands/proteins/transcription factors and antibodies. Compositions for use with this method are disclosed.

Japanese Abstract

Procede d'encapsulation d'acides nucleiques lies ou co-existants avec d'autres molecules qui facilitent l'absorption et l'integration de materiel genetique dans des cellules vivantes a l'aide d'ADN/ARN a liberation lente ou d'oligonucleotides combines a des facteurs de transcription/proteines/ligands de surface cellulaire et d'anticorps. On decrit egalement des compositions destinees a etre utilisees avec ce procede.

9/3,AB/60 (Item 33 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00315724

GANGLIOSIDES WITH IMMUNOSUPPRESSIVE CERAMIDE MOIETIES
GANGLIOSIDES COMPRENANT DES FRACTIONS DE CERAMIDES A EFFET
IMMUNOSUPPRESSEUR

Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor(s):

LADISCH Stephan

Patent and Priority Information (Country, Number, Date):

Patent: WO 9302686 A1 19930218

Application: WO 92US6358 19920730 (PCT/WO US9206358)

Priority Application: US 91738591 19910731

Designated States: CA JP AT BE CH DE DK ES FR GB GR IT LU MC NL SE

Publication Language: English

Fulltext Word Count: 8811

English Abstract

A method for suppressing immune responses in animals by administering a mixture of gangliosides to the animal where the gangliosides have heterogeneous ceramide structures containing fatty acid portions with carbon chain lengths of 21-30 or less than 18 carbon atoms. Ganglioside

mixtures which are homogeneous with respect to the fatty acid portion are also effective immunosuppressive agents when the carbon chain length of the fatty acid portion is less than 18. Compositions containing the above specified ganglioside mixtures are also disclosed.

Japanese Abstract

Procédé de suppressions de réponses immunitaires chez des animaux par administration d'un mélange de gangliosides présentant des structures hétérogènes de céramides contenant des parties d'acide gras avec des longueurs de chaîne carbonée de 21 à 30 ou inférieures à 18 atomes de carbone. Des mélanges de gangliosides qui sont homogènes par rapport à la partie d'acide gras sont également des agents immunosuppresseurs efficaces lorsque la longueur de la chaîne carbonée de la partie d'acide gras est inférieure à 18. L'invention concerne également des compositions contenant lesdits mélanges de gangliosides.

9/3,AB/61 (Item 34 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00307184

GANGLIOSIDES WITH IMMUNOSUPPRESSIVE ACTIVITY
GANGLIOSIDES PRESENTANT UNE ACTIVITE D'IMMUNODEPRESSION
Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor(s):

LADISCH Stephen

Patent and Priority Information (Country, Number, Date):

Patent: WO 9217189 A1 19921015

Application: WO 92US2624 19920327 (PCT/WO US9202624)

Priority Application: US 91677437 19910329

Designated States: AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE

Publication Language: English

Fulltext Word Count: 7504

English Abstract

A method for suppressing immune responses in animals by administering gangliosides to the animal. Gangliosides having terminal sialic acid groups are disclosed as being especially effective as immunosuppressive agents. The especially effective immunosuppressive gangliosides include GM4 and GM5. Ganglioside compositions for use in suppressing immune responses are also disclosed.

Japanese Abstract

Procédé servant à déprimer la réponse immunitaire chez les animaux par l'administration de gangliosides. Les gangliosides possédant des groupes d'acide salivaire en fin de chaîne sont tout particulièrement efficaces en tant qu'agents immunodépresseurs. Le GM4 et le GM5 comptent parmi les gangliosides immunodépresseurs particulièrement efficaces. On a également prévu des compositions de gangliosides destinées à la dépression des réponses immunitaires.

9/3,AB/62 (Item 1 from file: 348)
DIALOG(R) File 348:European Patents
(c) 2001 European Patent Office. All rts. reserv.

00682246

A sustained release composition comprising a multivalent cation cross-linked alginate combined with a polyacrylic acid
Zusammensetzung mit verzögerter Wirkstoffabgabe enthaltend ein multivalentes Kation veretztes Alginat kombiniert mit einem Polyacrylsäure

Composition a liberation prolongee comprenant un alginate reticule multivalent cationique combine avec un acide polyacrylique

PATENT ASSIGNEE:

BRISTOL-MYERS SQUIBB COMPANY, (205416), 345 Park Avenue, New York, N.Y.
10154-0037, (US), (applicant designated states:
AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)
UNIVERSITY OF WASHINGTON, (2243810), Office of Technology Transfer, 1107
NE 45th Street, Suite 200, Seattle, WA 98105, (US), (applicant
designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

Gombotz, W. R., 6406 N.E. 129th Place, Kirkland, Washington 98034, (US)
Mumper, R. J., 1812 Crooked Creed Road, Greenville, North Carolina 27858,
(US)
Bouchard, L. S., 2223 Benson Road S Apt. T202, Renton, Washington 98055,
(US)
Hoffman, A. S., 4528 West Laurel Drive N.E., Seattle, Washington 98105,
(US)

LEGAL REPRESENTATIVE:

White, Martin Paul et al (74783), Kilburn & Strode, 30 John Street,
London WC1N 2DD, (GB)

PATENT (CC, No, Kind, Date): EP 652015 A2 950510 (Basic)
EP 652015 A3 950802
EP 652015 B1 970319

APPLICATION (CC, No, Date): EP 94307259 941004;

PRIORITY (CC, No, Date): US 138367 931015

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;
NL; PT; SE

INTERNATIONAL PATENT CLASS: A61K-047/36; A61K-047/38; A61K-047/32;
A61K-038/00; A61K-038/27;

ABSTRACT EP 652015 A2

Alginate beads are employed as a site specific oral delivery system for cationic therapeutic agents, such as TGF-b(sub 1), designed to target the agents to the luminal side of the small intestine. Improved delivery of bioactive material is obtained by: 1) incorporating selected polyanions in the alginate beads to shield the cationic therapeutic agent from interaction with alginate and/or 2) acid treating alginate beads containing the therapeutic agents to reduce the molecular weight of alginate and its interaction with the agents. Enhanced bioactivity of therapeutic agents released from the alginate is attributed to the ability of polyacrylic acid to shield the agents from interaction with lower molecular fragments of acid treated alginate.

ABSTRACT WORD COUNT: 114

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB95	363
SPEC A	(English)	EPAB95	8970
Total word count - document A			9333
Total word count - document B			0
Total word count - documents A + B			9333

9/3,AB/63 (Item 2 from file: 348)

DIALOG(R)File 348:European Patents

(c) 2001 European Patent Office. All rts. reserv.

00269010

Improved method of obtaining immune regulatory factors by mammal immunization.

Verfahren zum Erhalten von immunregulierenden Faktoren mittels Säugetierimmunisierung.

Methode d'obtention de facteurs immunoregulateurs par immunisation de mammiferes.

PATENT ASSIGNEE:

THE STOLLE RESEARCH AND DEVELOPMENT CORPORATION, (285440), 6990 Cornell
Road, Cincinnati Ohio 45242, (US), (applicant designated states:

AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

Beck, Lee R., 2550 Dunmore Place, Birmingham, AL 35226, (US)

LEGAL REPRESENTATIVE:

Burford, Anthony Frederick (28961), W.H. Beck, Greener & Co. 7 Stone
Buildings Lincoln's Inn, London WC2A 3SZ, (GB)

PATENT (CC, No, Kind, Date): EP 300102 A1 890125 (Basic)
EP 300102 B1 930324

APPLICATION (CC, No, Date): EP 87306455 870721;

PRIORITY (CC, No, Date): EP 87306455 870721

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: A61K-039/00; A61K-009/52; A61K-039/40;
A61K-037/02; A61K-035/20

ABSTRACT EP 300102 A1

Immune regulatory factors, eg. antibodic and lymphokinens, are obtained by collecting or extracting immune regulatory factors containing substances, eg. milk, from mammals, especially bovids, immunized by administering an antigenic substance incorporated within a shaped structure of a biocompatible matrix material. The matrix material causes controlled release of the antigenic substance thereby prolonging antigenic activity within the treated animal.

ABSTRACT WORD COUNT: 62

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	681
CLAIMS B	(German)	EPBBF1	584
CLAIMS B	(French)	EPBBF1	648
SPEC B	(English)	EPBBF1	4781
Total word count - document A			0
Total word count - document B			6694
Total word count - documents A + B			6694

9/3,AB/64 (Item 1 from file: 652)

DIALOG(R)File 652:US Patents Fulltext

(c) format only 2001 The Dialog Corp. All rts. reserv.

00835685

Utility

STRUCTURED BIOERODIBLE DRUG DELIVERY DEVICE

PATENT NO.: 3,962,414

ISSUED: June 08, 1976 (19760608)

INVENTOR(s): Michaels, Alan S., Atherton, CA (California), US (United
States of America)

ASSIGNEE(s): Alza Corporation, (A U.S. Company or Corporation), Palo Alto
, CA (California), US (United States of America)
[Assignee Code(s): 2490]

APPL. NO.: 5-517,982

FILED: October 25, 1974 (19741025)

This is a division of application Ser. No. 248,168, filed Apr. 27, 1972
and now U.S. Pat. No. 3,867,519.

FULL TEXT: 1707 lines

ABSTRACT

A drug delivery device for the continuous and controlled administration of a predetermined therapeutically effective dosage of eye drug to the eye of a mamallian patient over a prolonged period of time. The device meters the

flow of polylactic acid polymer micro-encapsulated eye drug by means of a drug release rate controlling material comprised of an anionic polyvalent metal cation cross-linked polyelectrolyte. The device bioerodes in the biological environment of the patient concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.

9/3,AB/65 (Item 2 from file: 652)
DIALOG(R)File 652:US Patents Fulltext
(c) format only 2001 The Dialog Corp. All rts. reserv.

00742120

Utility
BIOERODIBLE DRUG DELIVERY DEVICE

PATENT NO.: 3,867,519
ISSUED: February 18, 1975 (19750218)
INVENTOR(s): Michaels, Alan S., Atherton, CA (California), US (United States of America)
ASSIGNEE(s): Alza Corporation, (A U.S. Company or Corporation), US (United States of America)
[Assignee Code(s): 2490]
APPL. NO.: 5-248,168
FILED: April 27, 1972 (19720427)

FULL TEXT: 1741 lines

ABSTRACT

A drug delivery device for the continuous and controlled administration of a predetermined therapeutically effective dosage of drug to a mamallian patient over a prolonged period of time. The device meters the flow of drug by means of a drug release rate controlling material comprised of an anionic polyvalent metal cation cross-linked polyelectrolyte. The device bioerodes in the biological environment of the patient concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.

et	Items	Description
S1	10515	COACERVATE OR COACERVATION
S2	74108	S1 AND MICROPARTICLE? OR MICROCAPSULE?
S3	5051	S2 AND S1
S4	607	S3 AND BIODEGRADABLE
S5	199	S4 AND ANTIGEN
S6	65	S5 NOT PY>1998
S7	65	RD (unique items)
S8	8644	S7 AND COACERVATE OR COACERVATION
S9	65	S8 AND S7
S10	0	KWIC S9
S11	0	9 KWIC
S12	40	E1-E5
S13	30	RD (unique items)

? s s13 not py>1998

Processing

Processed 10 of 40 files ...

Processing

Processed 30 of 40 files ...

Completed processing all files

30 S13

26856778 PY>1998

S14 22 S13 NOT PY>1998

? t s14/3,ab/1-22

>>>No matching display code(s) found in file(s): 65, 342, 345, 764

14/3,AB/1 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

132269884 CA: 132(20)269884q JOURNAL

Novel oral drug delivery gateways for biotechnology products:
polypeptides and vaccines

AUTHOR(S): Brayden, David J.; O'Mahony, Daniel J.

LOCATION: Elan Pharmaceutical Technologies, Trinity College Dublin,
Dublin, Ire., 2

JOURNAL: Pharm. Sci. Technol. Today DATE: 1998 VOLUME: 1 NUMBER: 7

PAGES: 291-299 CODEN: PSTTF8 ISSN: 1461-5347

PUBLISHER ITEM IDENTIFIER: 1461-5347(98)00075-3 LANGUAGE: English

PUBLISHER: Elsevier Science Ltd.

14/3,AB/2 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

128248422 CA: 128(20)248422q JOURNAL

Binding and uptake of biodegradable poly(dl-lactide) micro- and
nanoparticles in intestinal epithelia

AUTHOR(S): McClean, Siobhan; Prosser, Ena; Meehan, Eucharia; O'Malley,
Denise; Clarke, Nuala; Ramtoola, Zeibun; Brayden, David

LOCATION: Elan Pharmaceutical Technologies, Trinity College, Dublin, Ire.

JOURNAL: Eur. J. Pharm. Sci. DATE: 1998 VOLUME: 6 NUMBER: 2 PAGES:

153-163 CODEN: EPSCED ISSN: 0928-0987 LANGUAGE: English PUBLISHER:

Elsevier Science Ireland Ltd.

English Abstract

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

Japanese Abstract

Selon l'invention, on utilise dans un but therapeutique des implants comprenant des agents actifs que l'on introduit dans un espace suprachoroidien ou dans une region avasculaire de l'oeil. La liberation des medicaments dans l'oeil est regulee et maintenue pendant de longues periodes de temps, sans qu'il y ait des niveaux importants de repartition des medicaments en dehors du site d'administration.

9/3,AB/56 (Item 29 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00379839

METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ANTIGENS FOR USE AS VACCINES
COMPOSITIONS ET PROCEDES DE MICROENCAPSULATION D'ANTIGENES A UTILISER .COMME VACCINS

Patent Applicant/Assignee:

GENENTECH INC

Inventor(s):

CLELAND Jeffrey L

LIM Amy

POWELL Michael Frank

Patent and Priority Information (Country, Number, Date):

Patent: WO 9511010 A1 19950427

Application: WO 94US11753 19941013 (PCT/WO US9411753)

Priority Application: US 93141796 19931022; US 93143555 19931025

Designated States: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 18322

English Abstract

Methods and compositions are provided for the encapsulation of antigens in PLGA microspheres for use as vaccines. Such microspheres can also contain adjuvants. Mixtures of microspheres are provided which release %antigen% at desired intervals to provide boosts with antigens.

Japanese Abstract

L'invention concerne les compositions et procedes de microencapsulation dans des microspheres de PLGA d'antigenes a utiliser comme vaccins. De telles microspheres peuvent egalement contenir des adjuvants. L'invention concerne egalement des microspheres capables de liberer l'antigene a intervalles specifiques pour assurer une administration par vagues de l'antigene.

9/3,AB/57 (Item 30 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00379837

METHODS AND COMPOSITIONS FOR MICROENCAPSULATION OF ADJUVANTS
PROCEDES ET COMPOSITIONS DE MICROENCAPSULATION D'ADJUVANTS

Patent Applicant/Assignee:

GENENTECH INC

Inventor(s):

CLELAND Jeffrey L

LIM Amy

14/3,AB/3 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

128200510 CA: 128(17)200510q JOURNAL
Heparin absorption across the intestine: effects of sodium
N-(8-(2-hydroxybenzoyl)amino)caprylate in rat in situ intestinal
instillations and in Caco-2 monolayers
AUTHOR(S): Brayden, David; Creed, Elizabeth; O'connell, Alan; Leipold,
Harry; Agarwal, Rajesh; Leone-Bay, Andrea
LOCATION: Elan Pharmaceutical Technologies, Trinity College, Dublin, Ire.
, 2
JOURNAL: Pharm. Res. DATE: 1997 VOLUME: 14 NUMBER: 12 PAGES:
1772-1779 CODEN: PHREEB ISSN: 0724-8741 LANGUAGE: English PUBLISHER:
Plenum Publishing Corp.

14/3,AB/4 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

127185657 CA: 127(14)185657b JOURNAL
A novel in vitro electrophysiological bioassay for transport of
loperamide across intestinal epithelia
AUTHOR(S): Brayden, David; Moriarty, Derek; Baird, Alan
LOCATION: Trinity College, Elan Pharmaceutical Technologies, Dubin, Ire.,
JOURNAL: Pharm. Res. DATE: 1997 VOLUME: 14 NUMBER: 7 PAGES: 942-945
CODEN: PHREEB ISSN: 0724-8741 LANGUAGE: English PUBLISHER: Plenum

14/3,AB/5 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

126301309 CA: 126(23)301309v JOURNAL
Human intestinal epithelial cell monolayers as prescreens for oral drug
delivery
AUTHOR(S): Brayden, David J.
LOCATION: In Vitro Pharmacology Research Group, Elan Corp., Ire.,
JOURNAL: Pharm. News DATE: 1997 VOLUME: 4 NUMBER: 1 PAGES: 11-15
CODEN: PHNEEP ISSN: 1071-894X LANGUAGE: English PUBLISHER: Harwood

14/3,AB/6 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

126282763 CA: 126(21)282763v BOOK
Current Topics in Peptide Delivery. (Proceedings of CRS Ireland Special
Symposium, held at Trinity College, Dublin, Ireland, 20-22 September 1995.
(In: J. Controlled Release, 1997; 46(1,2))
AUTHOR(S): Brayden, David; Editor
LOCATION: Neth.
DATE: 1997 PAGES: 198 pp. CODEN: BOOKA7 LANGUAGE: English PUBLISHER:
(Elsevier, Amsterdam, Neth.)

14/3,AB/7 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

126152261 CA: 126(12)152261u JOURNAL
Non-antibiotic anti-diarrheal drugs: factors affecting oral
bioavailability of berberine and loperamide in intestinal tissue
AUTHOR(S): Baird, Alan W.; Taylor, Cormac T.; Brayden, David J.
LOCATION: Department of Pharmacology, University College Dublin, Dublin,

Ire., 4

JOURNAL: Adv. Drug Delivery Rev. DATE: 1997 VOLUME: 23 NUMBER: 1-3
PAGES: 111-130 CODEN: ADDREP ISSN: 0169-409X LANGUAGE: English
PUBLISHER: Elsevier

14/3,AB/8 (Item 8 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

124270303 CA: 124(20)270303r JOURNAL

Passive transepithelial diltiazem absorption across intestinal tissue
leading to tight junction openings

AUTHOR(S): Brayden, D. J.; Creed, E.; Meehan, E.; O'Malley, K. E.

LOCATION: Elan Corporation Research Institute, Trinity College, Dublin,

Ire., 2

JOURNAL: J. Controlled Release DATE: 1996 VOLUME: 38 NUMBER: 2,3

PAGES: 193-203 CODEN: JCREEC ISSN: 0168-3659 LANGUAGE: English

14/3,AB/9 (Item 9 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

122151316 CA: 122(13)151316w JOURNAL

Rabbit Peyer's patches: a novel physiological signature in response to
cholinomimetics

AUTHOR(S): Brayden, D. J.; Kelly, J. G.

LOCATION: Drug Delivery Research Unit, Trinity College, Dublin, Ire., 2

JOURNAL: Proc. Int. Symp. Controlled Release Bioact. Mater. DATE: 1994

VOLUME: 21ST, PAGES: 276-7 CODEN: PCRMEY ISSN: 1022-0178 LANGUAGE:
English

14/3,AB/10 (Item 10 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

122101081 CA: 122(9)101081v JOURNAL

Cultured human sweat gland epithelia: isolation of glands using neutral
red

AUTHOR(S): Brayden, David J.; Fitzpatrick, Joan

LOCATION: Elan Corporation Research Institute, Trinity College Dublin,
Dublin, Ire.,

JOURNAL: Pharm. Res. DATE: 1995 VOLUME: 12 NUMBER: 1 PAGES: 171-5

CODEN: PHREEB ISSN: 0724-8741 LANGUAGE: English

14/3,AB/11 (Item 11 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

121222732 CA: 121(19)222732w JOURNAL

A distinctive electrophysiological signature from the Peyer's patches of
rabbit intestine

AUTHOR(S): Brayden, D. J.; Baird, A. W.

LOCATION: Dep. Pharmacology, Univ. Coll. Dublin, Dublin, Ire.,

JOURNAL: Br. J. Pharmacol. DATE: 1994 VOLUME: 113 NUMBER: 2 PAGES:

593-9 CODEN: BJPCBM ISSN: 0007-1188 LANGUAGE: English

14/3,AB/12 (Item 12 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

121196513 CA: 121(17)196513d CONFERENCE PROCEEDING

A novel electrophysiological signature from the Peyer's patches of rabbit intestine

AUTHOR(S): Brayden, D.J.; Kelly, J.G.

LOCATION: Drug Delivery Res. Unit, Elan Corp., Dublin, Ire.,

JOURNAL: In Vitro Ex Vivo Test Syst. Ration. Drug Des. Delivery, Minutes, Eur. Symp. EDITOR: Crommelin, Daan (Ed), Couvreur, Patrick (Ed), Duchene, Dominique (Ed), DATE: 1994 PAGES: 217-21 CODEN: 60DSAB LANGUAGE: English MEETING DATE: 930000 PUBLISHER: Ed. Sante, Paris, Fr

14/3,AB/13 (Item 13 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

118188701 CA: 118(19)188701m JOURNAL

Stilbenes stimulate T84 chloride secretion by elevating calcium

AUTHOR(S): Brayden, David J.; Krouse, Mauri E.; Law, Tina; Wine, J. J.

LOCATION: Cystic Fibrosis Res. Lab., Stanford Univ., Stanford, CA,

94305-2130, USA

JOURNAL: Am. J. Physiol. DATE: 1993 VOLUME: 264 NUMBER: 2, Pt. 1

PAGES: G325-G333 CODEN: AJPHAP ISSN: 0002-9513 LANGUAGE: English

14/3,AB/14 (Item 14 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

116253513 CA: 116(25)253513b JOURNAL

Cystic fibrosis, the CFTR, and rectifying chloride channels

AUTHOR(S): Wine, J. J.; Brayden, D. J.; Hagiwara, G.; Krouse, M. E.; Law, T. C.; Muller, U. J.; Solc, C. K.; Ward, C. L.; Widdicombe, J. H.; Xia, Y.

LOCATION: Cystic Fibrosis Res. Lab., Stanford Univ., Stanford, CA, USA

JOURNAL: Adv. Exp. Med. Biol. DATE: 1991 VOLUME: 290 NUMBER: Identif.

CF (Cystic Fibrosis) Gene PAGES: 253-72 CODEN: AEMBAP ISSN: 0065-2598

LANGUAGE: English

14/3,AB/15 (Item 15 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

115204419 CA: 115(19)204419w JOURNAL

Synchronous transporting activity in epithelial cells in relation to intracellular calcium concentration

AUTHOR(S): Pickles, R. J.; Brayden, D. J.; Cuthbert, A. W.

LOCATION: Dep. Pharmacol., Univ. Cambridge, Cambridge, UK, CB2 1QJ

JOURNAL: Proc. R. Soc. London, Ser. B DATE: 1991 VOLUME: 245 NUMBER:

1312 PAGES: 53-8 CODEN: PRLBA4 ISSN: 0080-4649 LANGUAGE: English

14/3,AB/16 (Item 16 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

114079647 CA: 114(9)79647v JOURNAL

Ion transport in cultured epithelia from human sweat glands: comparison of normal and cystic fibrosis tissues

AUTHOR(S): Brayden, D. J.; Pickles, R. J.; Cuthbert, A. W.

LOCATION: Dep. Pharmacol., Univ. Cambridge, Cambridge, UK, CB2 1QJ

JOURNAL: Br. J. Pharmacol. DATE: 1991 VOLUME: 102 NUMBER: 1 PAGES:

57-64 CODEN: BJPCBM ISSN: 0007-1188 LANGUAGE: English

14/3,AB/17 (Item 17 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

112176455 CA: 112(19)176455x JOURNAL
Altered sensitivity to amiloride in cystic fibrosis. Observations using
cultured sweat glands
AUTHOR(S): Cuthbert, A. W.; Brayden, D. J.; Dunne, A.; Smyth, R. L.;
Wallwork, J.
LOCATION: Dep. Pharmacol., Univ. Cambridge, Cambridge, UK, CB2 1QJ
JOURNAL: Br. J. Clin. Pharmacol. DATE: 1990 VOLUME: 29 NUMBER: 2
PAGES: 227-34 CODEN: BCPHBM ISSN: 0306-5251 LANGUAGE: English

14/3,AB/18 (Item 18 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

112005395 CA: 112(1)5395y JOURNAL
Thapsigargin, a new calcium-dependent epithelial anion secretagogue
AUTHOR(S): Brayden, D. J.; Hanley, M. R.; Thastrup, O.; Cuthbert, A. W.
LOCATION: Dep. Pharmacol., Univ. Cambridge, Cambridge, UK, CB2 1QJ
JOURNAL: Br. J. Pharmacol. DATE: 1989 VOLUME: 98 NUMBER: 3 PAGES:
809-16 CODEN: BJPCBM ISSN: 0007-1188 LANGUAGE: English

14/3,AB/19 (Item 1 from file: 65)
DIALOG(R)File 65:Inside Conferences
(c) 2001 BLDSC all rts. reserv. All rts. reserv.

01520816 INSIDE CONFERENCE ITEM ID: CN015098237
Berberine, Enhancement of flux of a poorly absorbed anti- diarrhoeal agent
as indicated by electrogenic ion transport in rat colon and T84
%Brayden, D. J.; Bourke, E.; Baird, A. W.
CONFERENCE: Formulation of poorly-available drugs for oral administration
-European symposium
P: 191-194
France, Editions de Sante, 1996
ISBN: 2864110962
LANGUAGE: English DOCUMENT TYPE: Conference Papers
CONFERENCE EDITOR(S): Couvreur, P.; Duchene, D.; Kalles, I.
CONFERENCE SPONSOR: Association de Pharmacie Galenique Industrielle
Swedish Academy of Pharmaceutical Sciences
CONFERENCE LOCATION: Paris
CONFERENCE DATE: Feb 1996 (19960) (19960)

14/3,AB/20 (Item 2 from file: 65)
DIALOG(R)File 65:Inside Conferences
(c) 2001 BLDSC all rts. reserv. All rts. reserv.

00185271 INSIDE CONFERENCE ITEM ID: CN001860690
Cultured Human Sweat Gland Epithelia: Isolation of Glands Using Neutral
Red
Fitzpatrick, J. M.; Kelly, J. G.; %Brayden, D. J.%
CONFERENCE: Summer meeting
IRISH JOURNAL OF MEDICAL SCIENCE, 1994; VOL 163; NUMBER 2 P: 99
The Academy, 1994
ISSN: 0021-1265
LANGUAGE: English DOCUMENT TYPE: Conference Abstracts
CONFERENCE SPONSOR: Royal Academy of Medicine in Ireland Section of
Biomedical Sciences
CONFERENCE LOCATION: Coleraine
CONFERENCE DATE: Jun 1993 (199306) (199306)

14/3,AB/21 (Item 3 from file: 65)
DIALOG(R)File 65:Inside Conferences
(c) 2001 BLDSC all rts. reserv. All rts. reserv.

00185267 INSIDE CONFERENCE ITEM ID: CN001860653
Classic Ussing Chamber: Diltiazem Transport Across Rat Colon Epithelium
%Brayden, D. J.; Dunne, J.; Baird, A. W.; Kelly, J. G.
CONFERENCE: Summer meeting
IRISH JOURNAL OF MEDICAL SCIENCE, 1994; VOL 163; NUMBER 2 P: 97
The Academy, 1994
ISSN: 0021-1265
LANGUAGE: English DOCUMENT TYPE: Conference Abstracts
CONFERENCE SPONSOR: Royal Academy of Medicine in Ireland Section of
 Biomedical Sciences
CONFERENCE LOCATION: Coleraine
CONFERENCE DATE: Jun 1993 (199306) (199306)

14/3,AB/22 (Item 4 from file: 65)
DIALOG(R)File 65:Inside Conferences
(c) 2001 BLDSC all rts. reserv. All rts. reserv.

00063834 INSIDE CONFERENCE ITEM ID: CN000641261
Traditional Ussing Chamber: A Poor In Vitro Model for Drug Transport
Studies Across Epithelial Cells
%Brayden, D. J.; Kelly, J. G.
CONFERENCE: Methods to overcome biological barriers in drug delivery-
Symposium
KUOPIO UNIVERSITY PUBLICATIONS A PHARMACEUTICAL SCIENCES, 1993; NO 10
P: 62
Kuopio University, Department of Pharmaceutical Technology, 1993
ISSN: 1235-0478 ISBN: 9517805489
LANGUAGE: English DOCUMENT TYPE: Conference Extended abstracts
CONFERENCE EDITOR(S): Urtti, A.
CONFERENCE SPONSOR: University of Kuopio Department of Pharmaceutical
 Technology Center for Training and Development
CONFERENCE LOCATION: Kuopio, Finland
CONFERENCE DATE: Aug 1993 (199308) (199308)